Indazole-containing compound as well as pharmaceutical composition, preparation method and application thereof

By developing compounds containing indazole structures as PKMYT1 inhibitors, the problem of lacking highly effective and low-toxicity inhibitors in existing technologies has been solved, achieving effective inhibition of PKMYT1 and disease treatment.

CN118930534APending Publication Date: 2024-11-12SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410534314.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-04-30
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is a lack of highly effective and low-toxicity PKMYT1 inhibitors in the current technology to treat diseases related to PKMYT1 activity, especially in the case of CCNE1 gene amplification, where inhibition of PKMYT1 has shown synthetic lethality.

Method used

A class of compounds containing an indazole structure was developed as PKMYT1 inhibitors, exhibiting excellent inhibitory activity and favorable pharmacokinetic properties.

Benefits of technology

This compound can effectively inhibit PKMYT1 and can be used to prevent or treat diseases related to PKMYT1 activity. It has low toxicity and good pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930534A_ABST
    Figure CN118930534A_ABST
Patent Text Reader

Abstract

The invention relates to an indazole-containing compound, a pharmaceutical composition containing the same, and a preparation method and application of the indazole-containing compound. Specifically, the invention relates to a compound with a structure as shown in a formula (I), and the compound shows good inhibitory activity on membrane-related tyrosine / threonine protein kinase 1 (PKMYT1) and can be used for preventing or treating diseases or symptoms related to PKMYT1 activity. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicinal chemistry and relates to an indazole-containing compound used as a membrane-associated tyrosine / threonine protein kinase 1 (PKMYT1) inhibitor, a pharmaceutical composition containing the indazole-containing compound, a preparation method thereof and medical use thereof. Background Art

[0002] PKMYT1 (membrane-associated tyrosine / threonine protein kinase 1, also known as MYT1) is a class of protein kinases that belongs to the WEE protein kinase family and is involved in cell cycle regulation. The WEE protein kinase family includes three members: WEE1, WEE2, and MYT1. Among them, WEE1 and MYT1 are involved in regulating somatic cell mitosis, while WEE2 is involved in regulating germ cell meiosis. (GhelliLuserna di Rorà et al., AWEE1 family business: regulation of mitosis, cancer progression, and therapeutic target, Journal of hematology & oncology, (2020) 13: 126.).

[0003] In eukaryotic cells, PKMYT1 plays a key role in cell cycle regulation, mainly involved in the regulation of mitotic processes. Studies have shown that PKMYT1 acts on the G2 / M checkpoint and is not essential for normal cell cycle progression, while WEE1 acts on multiple checkpoints, including S, G2 / M, and M, and is essential for normal cell cycle progression, suggesting that inhibiting PKMYT1 may be less toxic to normal cells than inhibiting WEE1. Mechanistically, PKMYT1 inactivates the Cdk1 / CycB complex through phosphorylation, thereby promoting G2 checkpoint function and blocking the G2 / M transition of the cell cycle. PKMYT1 negatively regulates the Cdk1 / CycB complex mainly through two independent mechanisms: 1) PKMYT1 can phosphorylate Thr14 and Tyr15 on the substrate Cdk1, thereby inhibiting the activity of the Cdk1 / CycB complex and causing G2 / M arrest in the cell cycle; 2) PKMYT1 binds to Cdk1 and isolates it in the cytoplasm, preventing the Cdk1 / CycB complex from entering the nucleus, thereby preventing the cell cycle from progressing (Schmidt*M et al., Regulation of G2 / M Transition by Inhibition of WEE1 and PKMYT1Kinases, Molecules, 2017, 22(12): 2045; Wells NJ, et al., The C-terminal domain of the Cdc2inhibitory kinase Myt1 interacts with Cdc2 complexes and is required for inhibition of G2 / M progression, Journal of Cell Science,1999,112(19):3361-3371).

[0004] In tumor cells, in order to cope with the replication pressure brought by the high proliferation rate demand, PKMYT1 can ensure the repair of DNA damage in tumor cells by upregulating expression, maintain replication pressure and genomic stability of tumor cells, and thus play a tumor-promoting function. Inhibiting PKMYT1 forces the cell cycle of tumor cells that have not completed DNA damage repair to enter the next stage, resulting in the accumulation of DNA damage in tumor cells, increased genetic instability, inducing cell apoptosis and mitotic catastrophe, and achieving tumor suppression. David Gallo et al., CCNE1 amplification is synthetic lethal with PKMYT1kinase inhibition, Nature, 2022, 604(7907): 749-756. The study confirmed that CCNE1 can activate the MMB-FOXM1 transcription complex, thereby upregulating CDK1 and CCNB1 gene expression. In CCNE1 overexpressing cells, CyclinB and CDK1 expression are increased, and these cells are more sensitive to PKMYT1 inhibition, leading to synthetic lethality.

[0005] PKMYT1 and FBXW7 are key genes with synthetic lethality to CCNE1, among which PKMYT1 has the strongest dependence on CCNE1 gene amplification tumor cell lines. In addition, FBXW7 mutations are highly sensitive to PKMYT1 inhibitors, suggesting that FBXW7 is one of the synthetic lethal gene pairs of MYT1.

[0006] The MYT1 gene (mRNA level) is highly expressed in a variety of human tumors, such as gastric cancer, NSCLC, esophageal cancer, renal clear cell carcinoma, glioma, CRC, breast cancer, endometrial cancer, prostate cancer, head and neck squamous cell carcinoma, liver cancer, thyroid cancer, pancreatic cancer, bile duct cancer, etc. (Shao C, Wang Y, Pan M, et al. The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies [J]. Translational Lung Cancer Research, 2021, 10 (12): 4600).

[0007] In summary, in the case of CCNE1 gene amplification, inhibition of PKMYT1 showed synthetic lethality. Currently, there are no inhibitors targeting PKMYT1 on the market. Therefore, it is necessary to develop new, highly effective and low-toxic PKMYT1 inhibitors to meet clinical needs. Summary of the invention

[0008] The object of the present invention is to provide a new class of indazole-containing compounds, which have excellent inhibitory activity on PKMYT1, can be used to prevent or treat diseases or conditions related to PKMYT1 activity, and have good pharmacokinetic properties.

[0009] One aspect of the present invention provides a compound of formula (I) or a pharmaceutically acceptable form thereof:

[0010]

[0011] in:

[0012] X and Z are each independently selected from N or CR 2A ;

[0013] R 1 , R 2 and each R 2A are independently selected from hydrogen, halogen, hydroxyl, oxo, -CN, -NO 2 , -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -O(4-6 membered heterocycloalkyl), -S(C 1-6 Alkyl), -NR x R y 、-C(O)NH 2 、-C(O)(4-6 membered heterocycloalkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 Cycloalkyl), -C(O)NH(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 NR x R y , C 6-10 aryl and 5-10 membered heteroaryl; or R 1 Same as the adjacent R 2 or R 2A Together they form C 3-6 Alkylene; the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents;

[0014] R 3 Selected from hydrogen, halogen, C 1-6 Alkyl, C 3-4 Cycloalkyl or C 1-6 Haloalkyl;

[0015] R 4 and R 5 are each independently selected from hydrogen, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0016] R x and R y are each independently selected from hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)(C 1-6 alkyl), -C(O)(C 3-6 Cycloalkyl), -C(O)(4-6 membered heterocycloalkyl), -C(O)O(C 1-6 alkyl), -C(O)O(C 3-6 Cycloalkyl), -C(O)O(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 (C 3-6 Cycloalkyl) and -S(O) 2 (4-6 membered heterocycloalkyl); each of the alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, hydroxyl, oxo, -CN, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NH 2 、-NH(C 1-6 Alkyl), -NH(C 1-6 alkyl) 2 and substituted with a 4-6 membered heterocycloalkyl substituent;

[0017] The pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.

[0018] Another aspect of the present invention provides a pharmaceutical composition comprising a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof, and one or more pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0019] Another aspect of the present invention provides a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention, for use in preventing or treating a disease or condition associated with PKMYT1 activity, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0020] Another aspect of the present invention provides a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention for the preparation of a medicament for preventing or treating a disease or condition associated with PKMYT1 activity, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0021] Another aspect of the present invention provides a method for preventing or treating a disease or condition associated with PKMYT1 activity, the method comprising administering to an individual in need thereof an effective amount of a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0022] Another aspect of the invention provides processes for preparing the compounds of the invention.

[0023] General Terms and Definitions

[0024] Unless otherwise defined, the meaning of the terms used herein is the same as that commonly understood by those skilled in the art. The technical intent used herein refers to the technology commonly understood in the art, including changes or equivalent replacements of the technology that are obvious to those skilled in the art. Although the following terms are easily understood by those skilled in the art, they are still described below to better explain the present invention.

[0025] The terms "include", "comprising", "having" or "involving" and other variant forms thereof in this article refer to inclusive or open-ended collective concepts and do not exclude other unlisted elements or method steps. It should be understood by those skilled in the art that the above terms such as "comprising" include the meaning of "consisting of..."

[0026] The term "one or more" or the similar expression "at least one" means, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.

[0027] When the lower and upper limits of a numerical range are disclosed, any value or any sub-range falling within the range is specifically disclosed. In particular, each numerical range of a parameter disclosed herein (e.g., in the form of "about a to b", or equivalently "approximately a to b", or equivalently "about a b") should be understood to include every value and sub-range therein. For example, "C 1-6 " should be understood to include any sub-ranges and every point value therein, such as C 2-5 , C 3-4 , C 1-2 , C 1-3 , C 1-4 , C 1-5 etc., and C 1 , C 2 , C 3 , C 4 , C 5 , C 6 For another example, "3-10 yuan" should be understood to cover any sub-ranges and every point value therein, such as 3-4 yuan, 3-5 yuan, 3-6 yuan, 3-7 yuan, 3-8 yuan, 3-9 yuan, 4-5 yuan, 4-6 yuan, 4-7 yuan, 4-8 yuan, 5-7 yuan, 5-8 yuan, 6-7 yuan, etc., as well as 3, 4, 5, 6, 7, 8, 9, 10 yuan, etc.

[0028] When used alone or in combination with other groups herein, the term "alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group. 1-6 "Alkyl" refers to a saturated straight or branched hydrocarbon group having 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5 or 6 carbon atoms). For example, "C 1-6The term "alkyl" may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl, etc. The term "C1-4 alkyl" refers to a linear or branched aliphatic hydrocarbon chain having 1 to 4 carbon atoms (such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).

[0029] When used alone or in combination with other groups herein, the term "alkylene" refers to a saturated straight or branched chain divalent hydrocarbon group. For example, the term "C 1-6 The term "alkylene" refers to a saturated straight-chain or branched divalent hydrocarbon group having 1 to 6 carbon atoms, such as methylene, ethylene, propylene, butylene, pentylene, hexylene, and the like.

[0030] When used alone or in combination with other groups herein, the term "hydroxyalkyl" refers to an alkyl group substituted with one or more (such as 1 to 3) hydroxy groups. 1-6 "Hydroxyalkyl" refers to a hydroxyalkyl group having 1 to 6 carbon atoms, for example

[0031] As used herein, the term "cycloalkyl" refers to a saturated or partially saturated, monocyclic or polycyclic (such as bicyclic) non-aromatic hydrocarbon group; for example, a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclobutene, cyclopentene, cyclohexene; or a bicyclic ring including a spirocyclic ring, a fused ring or a bridged ring (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[5.2.0]nonyl or decahydronaphthyl, etc.). For example, the term "C 3-12 "Cycloalkyl" refers to a cycloalkyl group having 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9 or 10) ring carbon atoms. The term "C 3-8 "Cycloalkyl" refers to a cycloalkyl group having 3 to 8 ring carbon atoms, such as C 3-6 Cycloalkyl, which may be a monocyclic alkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, or a bicyclic alkyl, such as C 5-8 Spirocycloalkyl, C 5-8 Bridged cycloalkyl, C 5-8 Fused cycloalkyl, C 5-6 Spirocycloalkyl, C 5-6 Bridged cycloalkyl or C 5-6 Fused cycloalkyl.

[0032] When used alone or in combination with other groups herein, the term "heterocyclyl" or "heterocycloalkyl" refers to a saturated or partially saturated, monocyclic or polycyclic (such as bicyclic) non-aromatic group having one or more carbon atoms (such as 1, 2, 3, 4, 5, 6, 7, 8 or 9) and one or more (such as 1, 2, 3 or 4) heteroatoms independently selected from N, O, P and S in the ring. The term also covers the following situations, wherein the C atom or P atom in the ring can be replaced by an oxo group (=O), the S atom in the ring can be replaced by 1 or 2 oxo groups (=O), and the N atom on the ring can form a nitrogen oxide. "Heterocycle", "heterocyclyl" or "heterocycloalkyl" can have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ring atoms. The ring system in heterocycloalkyl can be a fused ring, a bridged ring or a spiro ring system. If the valence bond requirements are met, the heterocycloalkyl can be connected to other groups (or fragments) through any one carbon atom or heteroatom in the ring. For example, 3-12 membered, 3-8 membered, or 3-6 membered heterocycloalkyl groups include, but are not limited to, oxirane, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, dioxolanyl, dioxane, tetrahydrothiophenyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, and the like.

[0033] The term "saturated heterocycle" refers to a completely saturated heterocycle, such as tetrahydrofuran ring, piperidine ring, tetrahydropyran ring, piperazine ring, etc. The term "partially saturated heterocycle" refers to a heterocycle containing both saturated single bonds and unsaturated double bonds, such as 3,4-dihydro-2H-pyran, 1,2,3,4-tetrahydropyridine, 4,5-dihydroisoxazolyl, 4,5-dihydrooxazolyl, 2,5-dihydrooxazolyl, 2,3-dihydrooxazolyl, etc.

[0034] As used herein, the term "3-10 membered heterocyclyl" or "3-10 membered heterocycloalkyl" means a heterocyclyl group containing 3-10 ring atoms, including but not limited to a 4-10 membered heterocyclyl group, a 4-8 membered heterocyclyl group, a 4-7 membered heterocyclyl group, a 4-6 membered heterocyclyl group, a 5-6 membered heterocyclyl group, a 3-7 membered heterocyclyl group, a 4-6 membered nitrogen-containing heterocyclyl group, a 4-6 membered oxygen-containing heterocyclyl group, a 4-6 membered sulfur-containing heterocyclyl group, a 5-6 membered nitrogen-containing heterocyclyl group, a 5-6 membered oxygen-containing heterocyclyl group, a 5-6 membered sulfur-containing heterocyclyl group, and the like, wherein the "nitrogen-containing heterocyclyl group", "oxygen-containing heterocyclyl group" and "sulfur-containing heterocyclyl group" each optionally further contain one or more other heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of “4-6 membered heterocyclyl” or “4-6 membered heterocycloalkyl” include, but are not limited to, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, dioxolanyl, dioxanyl, tetrahydrothiophenyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl and the like.

[0035] When used alone or in combination with other groups herein, the term "aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (such as bicyclic) aromatic group having a conjugated π electron system. 6-10 The term "aryl" refers to an aromatic group containing 6 to 10 carbon atoms, such as phenyl or naphthyl.

[0036] When used alone or in combination with other groups herein, the term "heteroaryl" or "heteroaromatic ring" refers to an aromatic group having a conjugated π electron system, a monocyclic or condensed ring, and one or more carbon atoms (such as 1, 2, 3, 4, 5, 6, 9 or 10 carbon atoms) and one or more (such as 1, 2, 3 or 4) heteroatoms independently selected from N, O, P and S in the ring. Heteroaryl can be characterized by the number of ring atoms. For example, a 5-12 membered heteroaryl can contain 5-12 (such as 5, 6, 7, 8, 9, 10, 11 or 12) ring atoms, in particular 5, 6, 7, 8, 9, 10 ring atoms. If the valence bond requirements are met, the heteroaryl can be connected to the parent molecular moiety through any one of the ring atoms. For example, examples of heteroaryl groups include thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridine, pyrimidine, pyrazine, pyridazine, etc. The term also encompasses situations where the heteroaryl group may be optionally further fused to an aryl (e.g., benzene) or heteroaryl ring to form a fused ring system.

[0037] As used herein, the term "5-10 membered heteroaryl" or "5-10 membered heteroaromatic ring" means a heteroaromatic group (heteroaromatic ring) containing 5 to 10 (e.g., 5, 6, 7, 8, 9, 10) ring atoms, including 5-10 membered nitrogen-containing heteroaryl, 5-10 membered oxygen-containing heteroaryl, 5-10 membered sulfur-containing heteroaryl, 5-6 membered nitrogen-containing heteroaryl, 5-6 membered oxygen-containing heteroaryl, 5-6 membered sulfur-containing heteroaryl, etc. The "nitrogen-containing heteroaryl", "oxygen-containing heteroaryl" and "sulfur-containing heteroaryl" each optionally contain one or more other heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples include, but are not limited to, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, etc., or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and 5-10 membered cyclic groups containing these groups.

[0038] The term "condensed ring system (condensed ring)" refers to a polycyclic structure formed by two or more (e.g., 3, 4, or 5) carbocyclic rings or heterocyclic rings with a common ring edge, wherein the carbocyclic ring includes a cycloalkyl group and an aryl group, and the heterocyclic ring includes a heteroaryl group and a heterocycloalkyl group. The condensed ring system is, for example, a condensed ring system formed by a cycloalkyl group and a cycloalkyl group, a condensed ring system formed by a cycloalkyl group and a heterocycloalkyl group, a condensed ring system formed by a cycloalkyl group and an aryl group, a condensed ring system formed by a cycloalkyl group and a heteroaryl group, a condensed ring system formed by a heterocycloalkyl group and a heteroaryl group, a condensed ring system formed by a heterocycloalkyl group and an aryl group, a condensed ring system formed by a heteroaryl group and a heteroaryl group, a condensed ring system formed by a heteroaryl group and an aryl group, and the like.

[0039] As used herein, the term "alkenyl" alone or in combination with other groups refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon double bonds. 2-6 The term "alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms and one, two or three carbon-carbon double bonds (such as ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, etc.), which is optionally substituted by one or more (such as 1 to 3) substituents described herein.

[0040] When used alone or in combination with other groups herein, the term "alkenylene" refers to a straight or branched divalent aliphatic hydrocarbon group having one or more carbon-carbon double bonds, and the two groups (or fragments) connected thereto may be connected to the same carbon atom or to different carbon atoms. For example, the term "C 2-4 "Alkenylene" refers to an alkenylene group having 2 to 4 carbon atoms (e.g. , etc.), which are optionally substituted with one or more (e.g., 1-3) substituents described herein.

[0041] As used herein, the term "alkynyl" alone or in combination with other groups refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon triple bonds. 2-6 The term "alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms and one, two or three carbon-carbon triple bonds (e.g., ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, etc.), which is optionally substituted with one or more (e.g., 1 to 3) substituents described herein.

[0042] As used herein alone or in combination with other groups, the term "alkynylene" refers to a straight or branched divalent aliphatic hydrocarbon group having one or more carbon-carbon triple bonds, wherein the two groups (or fragments) connected thereto are respectively connected to different carbon atoms. 2-4 "Alkyne" refers to an alkynyl group having 2 to 4 carbon atoms (e.g. , etc.), which are optionally substituted with one or more (e.g., 1-3) substituents described herein.

[0043] The term "haloalkyl" or "halogen-substituted alkyl" as used herein, alone or in combination with other groups, refers to an alkyl group as described above in which one or more hydrogen atoms are replaced by a halogen. 1-6 "Haloalkyl" or "halogen-substituted C 1-6 "Alkyl" refers to a C 1-6 The term "C 1-4 "Haloalkyl" or "halogen-substituted C 1-4 "Alkyl" refers to a C 1-4 Those skilled in the art will appreciate that when there are more than one halogen substituent, the halogens may be the same or different and may be located on the same or different C atoms. Examples of haloalkyl groups include -CH 2 F, -CHF 2 , -CF 3 , -CCl 3 , -C 2 F 5 , -C 2 Cl 5 、-CH 2 CF 3 、-CH 2 Cl or -CH 2 CH 2 CF 3 wait.

[0044] The term "halo" or "halogen" group, when used herein alone or in combination with other groups, refers to F, Cl, Br or I.

[0045]

[0046] The term "hydroxy" as used herein alone or in combination with other groups refers to -OH.

[0046]

[0046] The term "cyano," as used herein alone or in combination with other groups, refers to -CN.

[0047] The term "nitro" as used herein, alone or in combination with other groups, refers to -NO 2 .

[0048] The term "amino" as used herein, alone or in combination with other groups, refers to -NH 2 .

[0049] The term "oxo," as used herein alone or in combination with other groups, refers to =0.

[0050] The term "each independently" or "independently" as used herein means that at least two groups (or fragments) with the same or similar value ranges present in the structure may have the same or different meanings under certain circumstances. For example, substituent X and substituent Y are each independently hydrogen, halogen, hydroxyl, -CN, alkyl or aryl. When substituent X is hydrogen, substituent Y may be either hydrogen or halogen, hydroxyl, -CN, alkyl or aryl; similarly, when substituent Y is hydrogen, substituent X may be either hydrogen or halogen, hydroxyl, -CN, alkyl or aryl.

[0051] The term "substituted" and its other variant forms in this article refer to one or more (such as 1, 2, 3 or 4) atoms or atomic groups (such as hydrogen atoms) on the specified atom being replaced by other equivalents, provided that the normal valence of the specified atom or atomic group in the current situation is not exceeded, and a stable compound can be formed. If a certain atom or atomic group is described as "optionally substituted by...", it can be substituted or unsubstituted. Unless otherwise indicated, the attachment site of the substituent herein can be from any suitable position of the substituent. When the connecting bond in the substituent is shown as a chemical bond between two atoms connected to each other through the ring system, it means that the substituent can be connected to any ring-forming atom in the ring system.

[0052] Whenever the term "alkyl" or "aryl" or any of their prefix roots appears in the name of a substituent, by itself or as part of another substituent, unless otherwise indicated, it should be interpreted as including the limitations given above for "alkyl" and "aryl". The number of carbon atoms specified (e.g., C l-6 ) shall independently refer to the number of carbon atoms in an alkyl portion or to the number of carbon atoms in the alkyl portion of a larger substituent of which alkyl is the root of its prefix.

[0053] The term "chemical bond" refers to the strong force between two or more adjacent atoms (or ions) in a pure molecule or crystal that binds them together, mainly including covalent bonds, ionic bonds, metallic bonds, coordination bonds, etc. Unless otherwise specified, the chemical bonds in the compounds of the present invention that exist in free form are mostly covalent bonds.

[0054] The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present invention that is substantially non-toxic to an organism. Pharmaceutically acceptable salts of the compound of the present invention include acid addition salts and base addition salts thereof. For example, hexafluorophosphate, meglumine salt, etc. For a review of suitable salts, see Stahl and Wermuth's "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002). Methods for preparing pharmaceutically acceptable salts of the compound of the present invention are known to those skilled in the art.

[0055] The term "pharmaceutically acceptable ester" refers to an ester which is substantially non-toxic to organisms and is hydrolyzed in vivo to form the compound of the present invention or a salt thereof. In addition, the compound of the present invention itself may also be an ester.

[0056] The term "isomers" refers to compounds that have the same number of atoms and types of atoms and therefore the same molecular weight, but differ in the arrangement or configuration of the atoms in space.

[0057] The term "stereoisomer" (or "optical isomer") refers to a stable isomer that has a vertical asymmetric plane due to at least one chiral factor (including chiral center, chiral axis, chiral plane, etc.), thereby being able to rotate plane polarized light. Since the compounds of the present invention have asymmetric centers and other chemical structures that may cause stereoisomerism, the present invention also includes these stereoisomers and mixtures thereof. Since the compounds of the present invention (or their pharmaceutically acceptable salts) include asymmetric carbon atoms, they can exist in the form of single stereoisomers, racemates, enantiomers, and mixtures of diastereomers. Generally, these compounds can be prepared in the form of racemates. However, if desired, such compounds may be prepared or isolated as pure stereoisomers, i.e., single enantiomers or diastereomers, or mixtures enriched in a single stereoisomer (purity ≥99%, ≥98%, ≥97%, ≥96%, ≥95%, ≥90%, ≥85%, ≥80%, ≥75%, ≥70%, ≥65%, or ≥60%). As described below, single stereoisomers of a compound may be prepared synthetically from optically active starting materials containing the desired chiral center, or by preparing a mixture of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatography, use of a chiral resolving agent, or direct separation of the enantiomers on a chiral chromatographic column. Starting compounds of a particular stereochemistry may be either commercially available or prepared as described below and resolved by methods well known in the art. The term "enantiomer" refers to a pair of stereoisomers that have non-superimposable mirror images of each other. The term "diastereomer" or "diastereomer" refers to optical isomers that do not form mirror images of each other. The term "racemic mixture" or "racemate" refers to a mixture containing equal parts of a single enantiomer (i.e., an equimolar mixture of two R and S enantiomers). The term "non-racemic mixture" refers to a mixture containing unequal parts of a single enantiomer. Unless otherwise indicated, all stereoisomeric forms of the compounds of the present invention are within the scope of the present invention.

[0058] In this paper, solid lines (——), solid wedges ( ) or virtual wedge ( ) to depict the covalent chemical bonds of the compounds of the invention. When a solid line is used to depict a bond to a chiral atom, all possible stereoisomers (e.g., a specific enantiomer, a racemic mixture, etc.) at that chiral atom are included. When a solid or dashed wedge is used to depict a bond to a chiral atom, the stereoisomer shown is present. Unless otherwise indicated, stereoisomers of the compounds of the invention may encompass specific enantiomers, diastereomers, racemates, or mixtures thereof in any ratio.

[0059] The term "tautomer" (or "tautomeric form") refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be achieved. For example, proton tautomers (or prototransfer tautomers) include (but are not limited to) interconversions through proton migration, such as keto-enol isomerization, imine-enamine isomerization, amide-imino alcohol isomerization, nitroso-oxime isomerization, etc. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.

[0060] The term "polymorph" (or "polymorphic form") refers to a solid crystalline form of a compound or complex. The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of multiple polymorphs in any proportion.

[0061] The term "solvate" refers to a substance formed by a compound of the invention (or a pharmaceutically acceptable salt thereof) and at least one solvent molecule bound by non-covalent intermolecular forces. The compounds of the invention may exist in the form of a solvate containing a polar solvent as a lattice structural element. The amount of the polar solvent may be present in a stoichiometric or non-stoichiometric ratio.

[0062] The term "isotopically labeled" refers to a derivative compound formed by replacing a specific atom in the compound of the present invention with an isotope atom thereof. Unless otherwise indicated, the compounds of the present invention include various isotopes of H, C, N, O, F, P, S, and Cl, such as 2 H(D), 3 H(T), 13 C. 14 C. 13 N. 15 N. 17 O. 18 O. 18 F. 31 P. 32 P. 34 S. 35 S. 36 S. 37 Cl and 125 I. For example, 12 C can be 13 C or 14 C substitution; 1 H can be 2 H (D, deuterium) or 3 H (T, tritium) substitution; 16 O can be 18 O substitution, etc.

[0063] Those skilled in the art will appreciate that, since nitrogen requires available lone pairs of electrons to be oxidized to oxides, not all nitrogen-containing heterocycles can form N-oxides. Those skilled in the art will recognize nitrogen-containing heterocycles that can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, including oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and metachloroperbenzoic acid (mCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyl dioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750 (AR Katritzky and AJ Boulton, Eds., Academic Press); and GWH Cheeseman and ES G Werstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392 (AR Katritzky and AJ Boulton, Eds., Academic Press).

[0064] The term "metabolite" refers to a derivative compound formed after the metabolism of the compound of the present invention, for example, produced by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis and the like. For further information on metabolism, see Goodman and Gilman's: The Pharmacological Basis of Therapeutics [M], McGraw-Hill International Editions, 1996. The present invention encompasses all possible metabolite forms of the compounds of the present invention, i.e., substances formed in the body of an individual to whom the compounds of the present invention are administered. Metabolites of the compounds can be identified by known techniques in the art, and their activity can be characterized by tests.

[0065] The term "prodrug" refers to a derivative compound that can directly or indirectly provide a compound of the present invention after being applied to an individual. Particularly preferred derivative compounds or prodrugs are compounds that can improve the bioavailability of the compound of the present invention when applied to an individual (e.g., more easily absorbed into the blood), or compounds that promote the delivery of the parent compound to the site of action (e.g., lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of the present invention are within the scope of the present invention, and various prodrug forms are known in the art, for example, see T.Higuchi, V.Stella, Pro-drugs as Novel Drug Delivery Systems [J], American Chemical Society, Vol.14, 1975. In addition, the present invention also encompasses compounds of the present invention containing protecting groups. In any process of preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive groups or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, such as the protecting groups described in TWGreene, PGM Wuts, Protective Groups in Organic Synthesis [M], John Wiley & Sons, 2006. These protecting groups may be removed at an appropriate subsequent stage using methods known in the art.

[0066] The present invention also encompasses methods for preparing the compounds described herein. It should be understood that the compounds of the present invention can be synthesized using the methods described below and synthetic methods known in the field of synthetic organic chemistry or variations thereof known to those skilled in the art. Preferred methods include (but are not limited to) those described below. The reaction can be carried out in a solvent or solvent mixture suitable for the reagents and materials used and suitable for achieving the transformation.

[0067] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating one or more symptoms of a target disorder or condition.

[0068] The term "FBXW7" refers to the F-box / WD repeat-containing protein 7 gene, transcript or protein. A mutated FBXW7 gene (FBXW7 gene with an inactivating mutation) is a gene that cannot produce a functional FBXW7 protein in a cell.

[0069] As used herein, the term "effective amount" (e.g., "therapeutically effective amount" or "prophylactically effective amount") refers to the amount of active ingredient that, after administration, will achieve the desired effect to some extent, such as alleviating one or more symptoms of the condition being treated or preventing the occurrence of the condition or its symptoms.

[0070] As used herein, unless otherwise indicated, the terms "treat," ...

[0071] As used herein, "individual" includes humans or non-human animals. Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals. "Non-human animals" in the present invention include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0072] Compound

[0073] In an embodiment of the present invention, the present invention provides a compound of formula (I) or a pharmaceutically acceptable form thereof:

[0074]

[0075] in:

[0076] X and Z are each independently selected from N or CR 2A ;

[0077] R 1 , R 2 and each R 2A are independently selected from hydrogen, halogen, hydroxyl, oxo, -CN, -NO 2 , -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -O(4-6 membered heterocycloalkyl), -S(C 1-6 Alkyl), -NR x R y 、-C(O)NH 2 、-C(O)(4-6 membered heterocycloalkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 Cycloalkyl), -C(O)NH(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 NR x R y , C 6-10 aryl and 5-10 membered heteroaryl; or R1 Same as the adjacent R 2 or R 2A Together they form C 3-6 Alkylene; the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl;

[0078] R 3 Selected from hydrogen, halogen, C 1-6 Alkyl, C 3-4 Cycloalkyl or C 1-6 Haloalkyl;

[0079] R 4 and R 5 are each independently selected from hydrogen, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0080] R x and R y are each independently selected from hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)(C 1-6 alkyl), -C(O)(C 3-6 Cycloalkyl), -C(O)(4-6 membered heterocycloalkyl), -C(O)O(C 1-6 alkyl), -C(O)O(C 3-6 Cycloalkyl), -C(O)O(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 (C 3-6 Cycloalkyl) and -S(O) 2 (4-6 membered heterocycloalkyl); each of the alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, hydroxyl, oxo, -CN, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NH 2 、-NH(C 1-6Alkyl), -NH(C 1-6 alkyl) 2 and substituted with a 4-6 membered heterocycloalkyl substituent;

[0081] The pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.

[0082] In certain embodiments, the present invention provides compounds of formula (I):

[0083] X and Z are each independently selected from N or CR 2A ;

[0084] R 1 , R 2 and each R 2A are independently selected from hydrogen, halogen, hydroxyl, oxo, -CN, -NO 2 , -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -O(4-6 membered heterocycloalkyl), -S(C 1-6 Alkyl), -NR x R y 、-C(O)NH 2 、-C(O)(4-6 membered heterocycloalkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 Cycloalkyl), -C(O)NH(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 NR x R y , C 6-10 aryl and 5-10 membered heteroaryl; or R 1 Same as the adjacent R 2 or R 2A Together they form C 3-6 Alkylene; the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR xR y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl;

[0085] R 3 Selected from hydrogen, halogen, C 1-6 Alkyl, C 3-4 Cycloalkyl or C 1-6 Haloalkyl;

[0086] R 4 and R 5 are each independently selected from hydrogen, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl;

[0087] R x and R y are each independently selected from hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)(C 1-6 alkyl), -C(O)(C 3-6 Cycloalkyl), -C(O)(4-6 membered heterocycloalkyl), -C(O)O(C 1-6 alkyl), -C(O)O(C 3-6 Cycloalkyl), -C(O)O(4-6 membered heterocycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 (C 3-6 Cycloalkyl) and -S(O) 2 (4-6 membered heterocycloalkyl); each of the alkyl, cycloalkyl or heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, hydroxyl, oxo, -CN, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NH 2 、-NH(C 1-6 Alkyl), -NH(C 1-6 alkyl) 2 and substituted by a 4- to 6-membered heterocycloalkyl substituent.

[0088] In certain embodiments, the present invention provides compounds of formula (I) wherein X is selected from N and CH.

[0089] In certain embodiments, the present invention provides compounds of formula (I), wherein Z is selected from N and -CR 2A , R 2A is selected from hydrogen, or R 2A With adjacent R 1 To form an optionally substituted -C3-6 Cycloalkyl.

[0090] In certain embodiments, the present invention provides compounds of formula (I) wherein Z is selected from N and -CH.

[0091] In certain embodiments, in the compound of formula (I) provided by the present invention, X is selected from N, and Z is selected from N; or, X is selected from N, and Z is selected from CH; or, X is selected from CH, and Z is selected from N; or, X is selected from CH, and Z is selected from CH.

[0092] In certain embodiments, the present invention provides compounds of formula (I), R 1 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl (preferably 4-8 membered heterocycloalkyl), -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0093] In certain embodiments, the present invention provides compounds of formula (I), R 1 Selected from hydrogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -C 1-4 Alkyl-OC 1-4 Alkyl-OH, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl) and -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8Cycloalkyl; the heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl -OH and -NR x R y substituted by a substituent.

[0094] In certain embodiments, the present invention provides compounds of formula (I), R 1 is selected from hydrogen, methyl, isopropyl, difluoromethyl, trifluoromethyl, cyclopropyl, Methoxy,

[0095] In certain embodiments, the present invention provides compounds of formula (I), R 1 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0096] In certain embodiments, the present invention provides compounds of formula (I), R 1 Selected from halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0097] In certain embodiments, the present invention provides compounds of formula (I), R 1 Selected from -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl.

[0098] In certain embodiments, the present invention provides compounds of formula (I), R 1 is selected from hydrogen, methyl, isopropyl, difluoromethyl, cyclopropyl,

[0099] In certain embodiments, the present invention provides compounds of formula (I), R 1 is selected from methyl, isopropyl, difluoromethyl, cyclopropyl,

[0100] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0101] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 3-6 Cycloalkyl), -S(O) 2 (C 1-4 Alkyl) and -S(O) 2 NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 Alkyl; the heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl) and -NR x R y substituted by a substituent.

[0102] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, methyl, isopropyl, fluoromethyl, trifluoromethyl, -SO 2 CH 3 、-SO 2 N(CH 3 ) 2 、-CH 2 OCH 3 ,

[0103] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -S(O) 2 (C 1-6 Alkyl), -S(O) 2 NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0104] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, -O(C 3-6 Cycloalkyl), -S(O) 2 (C 1-4 Alkyl) and -S(O) 2 NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 alkyl.

[0105] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, halogen, methyl, isopropyl, fluoromethyl, -SO 2 CH 3 、-SO 2 N(CH 3 ) 2 、-CH 2 OCH 3 .

[0106] In certain embodiments, the present invention provides compounds of formula (I), R 2 Selected from hydrogen, methyl, isopropyl, trifluoromethyl, -SO 2 CH 3 、-SO 2 N(CH 3 ) 2 、-CH 2 OCH 3 .

[0107] In certain embodiments, the present invention provides compounds of formula (I), R 2A Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl and -O(C 1-6 alkyl), the alkyl being optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0108] In certain embodiments, the present invention provides compounds of formula (I), R 2A Selected from hydrogen and -O(C 1-4 alkyl).

[0109] In certain embodiments, the present invention provides compounds of formula (I), R 2A is selected from hydrogen and methoxy.

[0110] In certain embodiments, the present invention provides compounds of formula (I), R 3 Selected from hydrogen, halogen, -C 1-6 Alkyl, each of which is optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 The substituents of the cycloalkyl and 4-6 membered heterocycloalkyl groups are substituted.

[0111] In certain embodiments, the present invention provides compounds of formula (I), R 3 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Halogenated alkyl.

[0112] In certain embodiments, the present invention provides compounds of formula (I), R 3 Selected from hydrogen, fluorine, chlorine, methyl, difluoromethyl, trifluoromethyl.

[0113] In certain embodiments, the present invention provides compounds of formula (I), R 4 Selected from hydrogen, halogen, -C 1-4 Alkyl and -C 1-4 Halogenated alkyl.

[0114] In certain embodiments, the present invention provides compounds of formula (I), R 4 Selected from hydrogen and fluorine.

[0115] In certain embodiments, the present invention provides compounds of formula (I), R 5Selected from hydrogen, halogen, -C 1-4 Alkyl and -C 1-4 Halogenated alkyl.

[0116] In certain embodiments, the present invention provides compounds of formula (I), R 5 Selected from hydrogen and fluorine.

[0117] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (IA):

[0118]

[0119] Among them, X, Z, R 1 , R 2 , R 3 , R 4 and R 5 As defined in formula (I).

[0120] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (II):

[0121]

[0122] Among them, Z, R 1 , R 2 , R 3 , R 4 and R 5 As defined in formula (I).

[0123] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (IIA):

[0124]

[0125] Among them, Z, R 1 , R 2 , R 3 , R 4 and R 5 As defined in formula (I).

[0126] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (III):

[0127]

[0128] Among them, R 1 , R 2 , R 3 , R 4 and R 5 As defined in formula (I).

[0129] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (IIIA):

[0130]

[0131] Among them, R 1 , R 2 , R 3 , R 4 and R 5 As defined in formula (I).

[0132] In certain embodiments, the compound represented by formula (I) is a compound represented by the following formula (IV):

[0133]

[0134] Among them, R 1 , R 2 , R 2A , R 3 As defined in formula (I).

[0135] In certain embodiments, in the compound of formula (IV):

[0136] R 1 Selected from hydrogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -C 1-4 Alkyl-OC 1-4 Alkyl-OH, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl) and -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl;

[0137] R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 3-6 Cycloalkyl), -S(O) 2 (C 1-4 Alkyl) and -S(O)2 NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 Alkyl; the heterocycloalkyl group is optionally selected from one or more independently selected from -NR x R y Substituents substituted, R x and R y are each independently selected from hydrogen and C 1-4 alkyl;

[0138] R 2A Selected from hydrogen and -O(C 1-4 alkyl);

[0139] R 3 Selected from hydrogen, halogen and -C 1-4 alkyl.

[0140] In certain embodiments, in the compound of formula (IV):

[0141] R 1 is selected from hydrogen, methyl, trifluoromethyl, cyclopropyl, Methoxy,

[0142] R 2 Selected from hydrogen, halogen, methyl, isopropyl, trifluoromethyl, -SO 2 CH 3 、-SO 2 N(CH 3 ) 2 、-CH 2 OCH 3 ,

[0143] R 2A is selected from hydrogen and methoxy;

[0144] R 3 is selected from hydrogen, chlorine and methyl.

[0145] The present invention covers any combination of the above embodiments.

[0146] In some embodiments, the present invention provides the following compounds or pharmaceutically acceptable forms thereof, including, but not limited to:

[0147]

[0148]

[0149]

[0150]

[0151] The pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.

[0152] Preparation method

[0153] The compounds of the present invention can be prepared by any method known in the art. Reagents and starting materials are readily available to those of ordinary skill in the art. Individual isomers, enantiomers, and diastereomers can be separated or split at any convenient point in the synthesis by methods such as selective crystallization techniques or chiral chromatography (See for example, J. Jacques, et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and EL Elel and SH Wilen).

[0154] The present invention provides a method for preparing a compound of formula I. In certain embodiments, the method comprises a fifth step, optionally a fourth step, optionally a third step, optionally a second step, and optionally a first step, wherein the first to fifth steps are as follows:

[0155] Step 1: Compound S-1 undergoes a coupling reaction with compound S-1-1 to generate compound S-2;

[0156]

[0157] Step 2: Compound S-2 removes the leaving group to generate compound S-3;

[0158]

[0159] Step 3: Compound S-3 undergoes coupling reaction with compound S-3-1 to generate compound S-4;

[0160]

[0161] Step 4: Compound S-4 reacts with compound S-4-1 to generate compound S-5;

[0162]

[0163] Step 5: Compound S-5 undergoes deprotection and hydrolysis to generate compound I;

[0164]

[0165] in

[0166] Y 1 CR 4 ;

[0167] X 1 is halogen (such as iodine, bromine or chlorine) or C optionally substituted by halogen 1-6 Alkyl sulfonate (such as triflate), preferably halogen;

[0168] PG 1 is a protecting group for hydrogen or amino (such as methyl, tert-butyloxycarbonyl, trityl, tetrahydro-2H-pyran-2-yl, tert-butyldimethylsilyl, triisopropylsilyl, benzyl and methoxymethyl, etc.), preferably tetrahydro-2H-pyran-2-yl;

[0169] LG 1 A leaving group that is hydrogen or amino (such as benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, etc.); is the leaving group of the amino group, where LG 2 is phenyl, 4-methoxyphenyl, etc., preferably phenyl;

[0170] X, Z, R 1 , R 2 , R 3 , R 4 and R 5 The groups are as defined above.

[0171] In some embodiments of the present invention, the method for preparing the compound of formula I provided by the present invention comprises the first to fifth steps described above.

[0172] In some embodiments of the present invention, the coupling reaction in the first step is preferably carried out in the presence of a catalyst. The catalyst may be selected from Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 or PdCl 2 etc., preferably Pd 2 (dba) 3 In some embodiments of the present invention, the coupling reaction in the first step is preferably carried out in the presence of a ligand. The ligand may be selected from PPh 3, XPhos, XantPhos, SPhos, RuPhos, Dppf, BINAP or PCy 3 In some embodiments of the present invention, the coupling reaction in the first step is preferably carried out in the presence of a base. The base can be selected from t-BuOK, t-BuONa, LiHMDS, NaHMDS, KHMDS, K 3 PO 4 ,KOAc,Cs 2 CO 3 , K 2 CO 3 Or Na 2 CO 3 etc., preferably Cs 2 CO 3 In some embodiments of the present invention, the coupling reaction in the first step is preferably carried out in the presence of a solvent. The solvent may be selected from toluene, THF, 1,4-dioxane, THF, DCE or DMF, etc., preferably 1,4-dioxane. In some embodiments of the present invention, the coupling reaction in the first step is preferably carried out at a suitable reaction temperature. The reaction temperature may be 60-120°C.

[0173] In some embodiments of the present invention, the reaction of removing the leaving group in the second step can be carried out in an acid (such as hydrochloric acid, sulfuric acid, nitric acid, trifluoroacetic acid, methanesulfonic acid, trifluoromethanesulfonic acid, etc.) or under metal-catalyzed hydrogenation conditions, preferably metal-catalyzed hydrogenation; the metal catalyst used in the catalytic hydrogenation is palladium / carbon or palladium hydroxide / carbon, and the hydrogen source is hydrogen or ammonium formate, preferably ammonium formate. In some embodiments of the present invention, the reaction of removing the leaving group in the second step is carried out in a suitable solvent; the solvent can be selected from MeOH, EtOH, THF or DMF, etc., preferably MeOH. In some embodiments of the present invention, the reaction of removing the leaving group in the second step is carried out at a suitable reaction temperature; the reaction temperature can be 0-100°C.

[0174] In some embodiments of the present invention, the third step coupling reaction is preferably carried out in the presence of a catalyst. The catalyst may be selected from Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 or PdCl 2 etc., preferably Pd 2 (dba) 3 In some embodiments of the present invention, the third step coupling reaction is preferably carried out in the presence of a ligand. The ligand may be selected from PPh 3, XPhos, XantPhos, SPhos, RuPhos, Dppf, BINAP or PCy 3 In some embodiments of the present invention, the third step coupling reaction is preferably carried out in the presence of a base. The base can be selected from t-BuOK, t-BuONa, LiHMDS, NaHMDS, KHMDS, K 3 PO 4 ,KOAc,Cs 2 CO 3 , K 2 CO 3 Or Na 2 CO 3 etc., preferably Cs 2 CO 3 In some embodiments of the present invention, the third step coupling reaction is preferably carried out in a solvent. The solvent may be selected from toluene, THF, 1,4-dioxane, THF, DCE or DMF, etc., preferably 1,4-dioxane. In some embodiments of the present invention, the third step coupling reaction is preferably carried out at a suitable temperature. The reaction temperature may be 60-120°C.

[0175] In some embodiments of the present invention, the fourth step reaction is preferably carried out in the presence of a metal catalyst and a base. The catalyst used is Xphos-Pd-G3, Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 , PdCl 2 、Pd(PPh 3 ) 4 、Pd(dppf)Cl 2 or Pd(acac) 2 etc., preferably Pd(dppf)Cl 2 ; The bases that can be used are t-BuOK, t-BuONa, LiHMDS, NaHMDS, KHMDS, K 3 PO 4 ,KOAc,Cs 2 CO 3 , K 2 CO 3 Or Na 2 CO 3In some embodiments of the present invention, the fourth step reaction is carried out in a solvent; the solvent may be selected from toluene, THF, 1,4-dioxane, THF, DCE or DMF, etc., preferably 1,4-dioxane. In some embodiments of the present invention, the fourth step reaction is carried out at a suitable reaction temperature; the reaction temperature may be 20-120°C.

[0176] In some embodiments of the present invention, the deprotection and hydrolysis reactions in the fifth step are carried out in the presence of an acid. The acid used is concentrated hydrochloric acid, concentrated sulfuric acid, concentrated nitric acid, etc., preferably concentrated sulfuric acid. In some embodiments of the present invention, the deprotection and hydrolysis reactions in the fifth step are carried out at a suitable reaction temperature; the reaction temperature may be 20-80°C.

[0177] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (IA-8). The present invention provides a method for preparing a compound of formula (IA-8), which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), and optionally further comprises step (1), wherein steps (1) to (5) are as shown in route A:

[0178] Route A

[0179]

[0180] in:

[0181] R 1 and PG 1 As defined above, m and n are each independently 0, 1 or 2;

[0182] represents a 4-8 membered saturated or partially saturated heterocyclic ring containing N;

[0183] R 7 Selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl.

[0184] Step (1): Compound IA-1 reacts with IA-2 to generate compound IA-3.

[0185] In some embodiments of the present invention, the reaction conditions of step (1) are as described above for the coupling reaction of compound S-3 and compound S-3-1 to produce compound S-4.

[0186] Step (2): Compound IA-3 undergoes a ring-closure reaction to generate compound IA-4.

[0187] In some embodiments of the present invention, the reaction conditions of step (2) are as described above for the reaction of compound S-4 with compound S-4-1 to produce compound S-5.

[0188] Step (3): Protective group Boc on compound IA-4 generates compound IA-5.

[0189] In some embodiments of the present invention, the reaction of step (3) is preferably carried out under alkaline conditions. The base providing alkaline conditions can be selected from TEA, DIPEA or NaH, etc. In some embodiments of the present invention, the reaction of step (3) is preferably carried out in a solvent. The solvent used can be selected from DCM, THF or DMF, etc. In some embodiments of the present invention, the reaction of step (3) is preferably carried out at a suitable reaction temperature. The reaction temperature can be 0-100°C. In some embodiments of the present invention, the reaction of step (3) can be carried out under a catalyst. The catalyst is preferably DMAP.

[0190] Step (4): Compound IA-5 and IA-6 undergo coupling reaction to generate compound IA-7.

[0191] In some embodiments of the present invention, the coupling reaction of step (4) is preferably carried out in the presence of a catalyst. The catalyst may be selected from Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 or PdCl 2 etc., preferably Pd 2 (dba) 3 In some embodiments of the present invention, the coupling reaction of step (4) is preferably carried out in the presence of a ligand. The ligand may be selected from PPh 3 , t-BuXPhos, XantPhos, SPhos, RuPhos, Dppf, BINAP or PCy 3 In some embodiments of the present invention, the coupling reaction of step (4) is preferably carried out in the presence of a base. The base that can be used is t-BuOK, t-BuONa, KHMDS, K 3 PO 4 , Cs 2 CO 3 , K 2CO 3 Or Na 2 CO 3 etc.; In some embodiments of the present invention, the coupling reaction of step (4) is preferably carried out in a suitable solvent. The solvent may be selected from toluene, THF, 1,4-dioxane, THF, DCE or DMF, etc. In some embodiments of the present invention, the coupling reaction of step (4) is preferably carried out at a suitable reaction temperature. The reaction temperature may be 60-130°C.

[0192] Step (5): Compound IA-7 undergoes hydrolysis and deprotection reaction to generate compound IA-8.

[0193] In some embodiments of the present invention, the reaction conditions of step (5) are as described above for the deprotection and hydrolysis reaction of compound S-5 to generate compound I.

[0194] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (I-B1-2). The present invention provides a method for preparing a compound represented by formula (I-B1-2), which comprises step (2) and optionally further comprises step (1), wherein step (1) to step (2) are as shown in route B1:

[0195] Route B1

[0196]

[0197] in:

[0198] R 1 and PG 1 As defined above.

[0199] Step (1): Compound IB-0 undergoes coupling reaction to generate compound I-B1-1.

[0200] In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in the presence of sodium methoxide. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in the presence of a catalyst. The catalyst used can be selected from Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 etc., preferably Pd 2 (dba) 3. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in the presence of a ligand. The ligands that can be used are t-BuXPhos, XantPhos, SPhos, RuPhos, BINAP, etc., preferably t-BuXPhos. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in a suitable solvent. The solvent can be selected from toluene, THF, 1,4-dioxane, THF, DCE or DMF, etc., preferably 1,4-dioxane. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out at a suitable reaction temperature. The reaction temperature can be 60-130°C.

[0201] Step (2): Compound I-B1-1 undergoes hydrolysis and deprotection reaction to generate compound I-B1-2.

[0202] In some embodiments of the present invention, the reaction conditions are as described above for the deprotection and hydrolysis reaction of compound S-5 to generate compound I.

[0203] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (I-B2-7). The present invention provides a method for preparing a compound of formula (I-B2-7), which comprises step (6), optionally further comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), and steps (1) to (6) are as shown in route B2:

[0204] Route B2

[0205]

[0206] in:

[0207] R 1 and PG 1 As defined above for formula I. X is halogen, preferably bromine.

[0208] Step (1): Compound IB-0 undergoes hydrolysis reaction to generate compound I-B2-1.

[0209] In some embodiments of the present invention, the hydrolysis reaction of step (1) is preferably carried out in the presence of a base. The base can be selected from potassium hydroxide. In some embodiments of the present invention, the hydrolysis reaction of step (1) is preferably carried out in the presence of a catalyst. The catalyst can be selected from Pd(OAc) 2 , Pd 2 (dba) 3 、Pd(dba) 2 etc., preferably Pd 2 (dba)3 . In some embodiments of the present invention, the hydrolysis reaction of step (1) is preferably carried out in the presence of a ligand. The ligand may be selected from t-BuXPhos, XantPhos, SPhos, RuPhos, BINAP, etc., preferably t-BuXPhos. In some embodiments of the present invention, the hydrolysis reaction of step (1) is preferably carried out in a suitable solvent. The solvent may be selected from water, THF, 1,4-dioxane, DCE or DMF, etc., preferably a mixed solvent of 1,4-dioxane and water. In some embodiments of the present invention, the hydrolysis reaction of step (1) is preferably carried out at a suitable reaction temperature. The reaction temperature may be 60-130°C.

[0210] Step (2): Compound I-B2-1 is subjected to Boc protection to generate compound I-B2-2.

[0211] In some embodiments of the present invention, the reaction conditions of step (2) are as described in step (3) of route A.

[0212] Step (3): Compound I-B2-2 is deprotected to generate compound I-B2-3.

[0213] In some embodiments of the present invention, the deprotection reaction of step (3) is preferably carried out under alkaline conditions. The base providing alkaline conditions can be selected from LiOH, NaOH or KOH, preferably LiOH. In some embodiments of the present invention, the deprotection reaction of step (3) is carried out in a suitable solvent. The solvent can be selected from MeOH / H 2 O, MeOH / H 2 O or MeOH, THF and H 2 In some embodiments of the present invention, the deprotection reaction in step (3) is carried out at a suitable reaction temperature, which may be 0-60°C.

[0214] Step (4): Compound I-B2-3 reacts with I-B2-4 to generate compound I-B2-5.

[0215] In some embodiments of the present invention, the reaction of step (4) is preferably carried out under alkaline conditions. The base providing alkaline conditions can be selected from KHCO 3 、NaHCO 3 Or Na 2 CO 3 etc., preferably KHCO 3 In some embodiments of the present invention, the reaction of step (4) is carried out in a suitable solvent. The solvent may be selected from DMF, ACN or DMSO. In some embodiments of the present invention, the reaction of step (4) is carried out at a suitable reaction temperature. The reaction temperature may be 0-60°C.

[0216] Step (5): Compound I-B2-5 undergoes hydrolysis reaction to generate compound I-B2-6.

[0217] In some embodiments of the present invention, the hydrolysis reaction in step (5) is preferably carried out at K 2 CO 3 / H 2 O 2 The mixed system is reacted in DMSO as a solvent. In some embodiments of the present invention, the hydrolysis reaction of step (5) is carried out at a suitable reaction temperature, which may be 0-60°C.

[0218] Step (6): Compound I-B2-6 undergoes a deprotection reaction to generate compound I-B2-7.

[0219] In some embodiments of the present invention, the deprotection reaction of step (6) is preferably carried out in the presence of an acid. The acid used can be selected from concentrated hydrochloric acid, concentrated sulfuric acid, hydrochloric acid 1,4-dioxane solution, etc., preferably hydrochloric acid 1,4-dioxane solution. In some embodiments of the present invention, the deprotection reaction of step (6) is carried out at a suitable reaction temperature. The reaction temperature can be 0-60°C.

[0220] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (I-C1-6). The present invention provides a method for preparing a compound of formula (I-C1-6), which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), and the steps (5) to (1) are as shown in route C1:

[0221] Route C1

[0222]

[0223] in:

[0224] R 1 and PG 1 As defined above for formula I. n=0 or 1.

[0225] Step (1): Compound IB-0 undergoes a suzuki reaction with I-C1-1 to generate compound I-C1-2.

[0226] In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in the presence of a base. The base can be selected from potassium hydroxide, potassium carbonate, etc., preferably potassium carbonate. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in the presence of a catalyst. The catalyst used can be selected from Pd(OAc) 2, Pd 2 (dba) 3 、Pd(dppf)Cl 2 and t-BuXPhos-Pd-G3, etc., preferably t-BuXPhos-Pd-G3. In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out in a suitable solvent. The solvent can be selected from water, 1,4-dioxane, THF, DCE or DMF, etc., preferably a mixed solvent of 1,4-dioxane and water; In some embodiments of the present invention, the coupling reaction of step (1) is preferably carried out at a suitable reaction temperature. The reaction temperature can be 60-130°C.

[0227] Step (2): Compound I-C1-2 undergoes a Boc reaction to generate compound I-C1-3.

[0228] In some embodiments of the present invention, the reaction conditions of step (2) are as described in step (3) of route A.

[0229] Step (3): Compound I-C1-3 undergoes oxidation bond breaking and then reduction reaction to generate compound I-C1-4.

[0230] In some embodiments of the present invention, the reaction of step (3) is carried out in the presence of an oxidant. The oxidant is preferably ozone. In some embodiments of the present invention, the reaction of step (3) is carried out in a suitable solvent. The solvent is preferably a mixed solvent of DCM and MeOH. In some embodiments of the present invention, the reaction of step (3) is carried out at a suitable reaction temperature. The reaction temperature may be -78°C-0°C. In some embodiments of the present invention, the reaction of step (3) is carried out in the presence of a reducing agent. The reducing agent is preferably sodium borohydride.

[0231] Step (4): Compound I-C1-4 undergoes hydrolysis reaction to generate compound I-C1-5.

[0232] In some embodiments of the present invention, the hydrolysis reaction conditions of step (4) are as described in step (5) of route B2.

[0233] Step (5): Compound I-C1-5 undergoes a deprotection reaction to generate compound I-C1-6.

[0234] In some embodiments of the present invention, the reaction conditions of step (5) are as described in step (6) of route B2.

[0235] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (I-C2-3). The present invention provides a method for preparing a compound of formula (I-C2-3), which comprises step (3), optionally further comprises step (2), and optionally further comprises step (1), wherein steps (1) to (3) are as shown in route C2:

[0236] Route C2

[0237]

[0238] in:

[0239] R 1 and PG 1 As defined above. n=0 or 1.

[0240] Step (1): Compound I-C1-4 undergoes a substitution reaction to generate compound I-C2-1.

[0241] In some embodiments of the present invention, the substitution reaction of step (1) is preferably carried out in the presence of a catalyst. The catalyst may be selected from silver oxide, etc. In some embodiments of the present invention, the substitution reaction of step (1) is preferably carried out in a suitable solvent. The solvent may be selected from 1,4-dioxane, DCM or MeOH, etc. In some embodiments of the present invention, the substitution reaction of step (1) is carried out at a suitable reaction temperature. The reaction temperature may be 0-80°C.

[0242] Step (2): Compound I-C2-1 undergoes hydrolysis reaction to generate compound I-C2-2.

[0243] In some embodiments of the present invention, the hydrolysis reaction conditions of step (2) are as described in step (5) of route B2.

[0244] Step (3): Compound I-C2-2 undergoes a deprotection reaction to generate compound I-C2-3.

[0245] In some embodiments of the present invention, the deprotection reaction conditions of step (3) are as described in step (6) of route B2.

[0246] In some embodiments of the present invention, the compound represented by formula (I) is a compound represented by the following formula (I-C3-7). The present invention provides a method for preparing a compound of formula (I-C3-7), which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), and steps (1) to (5) are as shown in route C3:

[0247] Route C3

[0248]

[0249] in:

[0250] R 1 and PG 1 As defined above. X is halogen such as bromine, iodine, chlorine, preferably bromine.

[0251] Step (1): Compound I-C3-1 undergoes a halogenation reaction to generate compound I-C3-2.

[0252] In some embodiments of the present invention, the compound I-C3-1 preferably undergoes a bromination reaction in the halogenation reaction of step (1). The conditions for the bromination reaction are preferably PPh 3 / NBS、PPh 3 / CBr 4 POBr 3 etc., more preferably PPh 3 / NBS; In some embodiments of the present invention, the halogenation reaction of step (1) is preferably carried out in a solvent. The solvent may be selected from THF, DCM, CH 3 CN or DMF, etc. In some embodiments of the present invention, the halogenation reaction in step (1) is carried out at a suitable reaction temperature, which may be 0-60°C.

[0253] Step (2): Compound I-C3-2 undergoes a substitution reaction with I-C3-3 to generate compound I-C3-4.

[0254] In some embodiments of the present invention, the substitution reaction of step (2) is carried out in the presence of a base. The base can be selected from NaH, Cs 2 CO 3 , LDA, t-BuOK, t-BuONa, etc., preferably NaH. In some embodiments of the present invention, the substitution reaction in step (2) is preferably carried out in a solvent. The solvent can be selected from THF, DCM, DCE, CH 3 CN or DMF, etc. In some embodiments of the present invention, the substitution reaction in step (2) is carried out at a suitable reaction temperature, which may be 0-60°C.

[0255] Step (3): Compound I-C3-4 undergoes a Boc reaction to generate compound I-C3-5.

[0256] In some embodiments of the present invention, the reaction conditions of step (3) are as described in step (3) of route A.

[0257] Step (4): Compound I-C3-5 undergoes hydrolysis reaction to generate compound I-C3-6.

[0258] In some embodiments of the present invention, the hydrolysis reaction conditions of step (3) are as described in step (5) of route B2.

[0259] Step (5): Compound I-C3-6 undergoes a deprotection reaction to generate compound I-C3-7.

[0260] In some embodiments of the present invention, the deprotection reaction conditions of step (4) are as described in step (6) of route B2.

[0261] Those skilled in the art will appreciate that, depending on the desired product structure, one or more steps in the above-described preparation method may be omitted, and the order of the reaction steps may be appropriately adjusted as well as protection / deprotection reaction steps may be added or omitted as needed.

[0262] Pharmaceutical compositions, preparations and kits

[0263] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof, or a mixture thereof, and one or more pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotopically labeled, metabolite or prodrug.

[0264] A further object of the present invention is to provide a method for preparing the pharmaceutical composition of the present invention, which comprises combining the compound of the present invention or its pharmaceutically acceptable form or a mixture thereof with one or more pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotope labels, metabolites or prodrugs.

[0265] Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, sterile liquids. Pharmaceutically acceptable carriers include pharmaceutical excipients. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (2005).

[0266] The pharmaceutical composition can be administered in any form as long as it prevents, alleviates, prevents or cures the symptoms of a human or animal patient. For example, various suitable dosage forms can be prepared according to the administration route.

[0267] When administered orally, the pharmaceutical composition can be prepared into any oral acceptable preparation form.

[0268] When applied percutaneously or topically, the pharmaceutical composition may be formulated in a suitable ointment, lotion or liniment, wherein the active ingredient may be suspended or dissolved in one or more carriers.

[0269] The pharmaceutical composition can also be used in the form of injections, including injection solutions, sterile powders for injections and concentrated solutions for injections.

[0270] Another aspect of the present invention also relates to a pharmaceutical preparation comprising a compound of formula (I), (IA), (II), (IIA), (III) or (IIIA), a pharmaceutically acceptable form thereof or a mixture thereof as an active ingredient, or a pharmaceutical composition of the present invention, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug. In some embodiments, the preparation is in the form of a solid preparation, a semi-solid preparation, a liquid preparation or a gaseous preparation.

[0271] A further object of the present invention is to provide an article, for example, provided in the form of a kit. Articles used herein are intended to include, but are not limited to, pharmaceutical compositions and packaging. For example, the article of the present invention comprises: (a) a first container; (b) a pharmaceutical composition located in the first container, wherein the composition comprises: a first therapeutic agent, including: a compound of the present invention or a pharmaceutically acceptable form thereof, or a mixture thereof, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug; and (c) an optional package insert, which indicates that the pharmaceutical composition can be used to treat a disease or condition for which a MYT1 inhibitor is applicable, such as a tumor-like condition.

[0272] The package insert is a trademark, label, label, or the like, which lists information related to the pharmaceutical composition located in the first container. The listed information is usually determined by the regulatory agency (e.g., the U.S. Food and Drug Administration) that governs the area where the product is to be sold. Preferably, the package insert specifically lists the indications for which the pharmaceutical composition is approved. The package insert can be made of any material from which the information contained therein or thereon can be read. Preferably, the package insert is a printable material (e.g., paper, plastic, cardboard, foil, adhesive paper or plastic, etc.) on which the desired information can be formed (e.g., printed or applied).

[0273] Treatments and uses

[0274] The object of the present invention is to provide a compound of formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof or a pharmaceutical composition of the present invention for preventing or treating a disease or condition associated with PKMYT1 activity, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug. The disease or condition includes cancers with high expression of CCNE1 or with inactivating mutations in the FBXW7 gene.

[0275] Another object of the present invention is to provide a method for preventing or treating a disease or condition associated with PKMYT1 activity, the method comprising administering to an individual in need thereof an effective amount of a compound of Formula (I), (IA), (II), (IIA), (III) or (IIIA) or a pharmaceutically acceptable form thereof or a mixture thereof, or a pharmaceutical composition of the present invention, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0276] Another object of the present invention is to provide a compound of formula (I), formula (IA), formula (II), formula (IIA), formula (III) or formula (IIIA) or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention for the preparation of a medicament for preventing or treating a disease or condition associated with PKMYT1 activity, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0277] Another object of the present invention is to provide a compound of formula (I), formula (IA), formula (II), formula (IIA), formula (III) or formula (IIIA) or a pharmaceutically acceptable form thereof, or a pharmaceutical composition of the present invention for use in the preparation of a PKMYT1 inhibitor, wherein the pharmaceutically acceptable form is selected from a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope label, metabolite or prodrug.

[0278] According to some embodiments of the present invention, the PKMYT1 inhibitor is a compound disclosed in the present invention or a pharmaceutically acceptable form thereof.

[0279] According to some embodiments of the present invention, the disease or condition associated with PKMYT1 is a disease or condition that is dependent on PKMYT1 activity, including but not limited to tumor or cancer diseases or conditions.

[0280] According to some embodiments of the present invention, the disease or condition associated with PKMYT1 is a disease that is sensitive or responsive to a PKMYT1 inhibitor, including but not limited to tumor or cancer diseases or conditions.

[0281] According to some embodiments of the present invention, the disease or condition includes a disease or condition with symptoms of cell hyperproliferation. Further, the disease or condition with symptoms of cell hyperproliferation includes (but is not limited to) tumor or cancer diseases or conditions. Furthermore, the cancer is a cancer with high expression of CCNE1 gene / CCNE1 gene expansion or a cancer with an inactivating mutation of FBXW7 gene.

[0282] In some embodiments, the cancer with high CCNE1 gene expression or CCNE1 gene expansion is uterine cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, liver cancer or endometrial cancer.

[0283] In an embodiment of the present invention, the present invention provides a method of treating cancer, the method comprising administering to a subject an effective amount of a PKMYT1 inhibitor, wherein the cancer has an inactivating mutation in the FBXW7 gene.

[0284] The dosage regimen can be adjusted to provide the best desired response. For example, when the drug is administered in the form of an injection, a single push, a bolus injection, and / or a continuous infusion, etc., can be administered. For example, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the treatment situation. It should be noted that the dosage value may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. In general, the dosage of treatment varies, depending on considerations such as: the age, sex, and general health of the patient to be treated; the frequency of treatment and the nature of the desired effect; the degree of tissue damage; the duration of symptoms; and other variables that can be adjusted by individual physicians. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to individual needs and the professional judgment of the person administering the composition or supervising the administration of the composition. The dosage and administration regimen of the pharmaceutical composition can be determined by a person of ordinary skill in the clinical field. For example, the composition or compound of the present invention can be administered 4 times a day to once every 3 days in divided doses, and the dosage can be, for example, 0.01 to 1000 mg / time. The required dose may be administered in one or more doses to achieve the desired result.The pharmaceutical composition according to the present invention may also be provided in unit dosage form.

[0285] Beneficial Effects

[0286] The present invention provides a novel class of PKMYT1 inhibitors, which can achieve at least one of the following technical effects:

[0287] (1) High inhibitory activity against PKMYT1.

[0288] (2) Excellent physicochemical properties (e.g. solubility, physical and / or chemical stability).

[0289] (3) Excellent pharmacokinetic properties (e.g., good bioavailability, appropriate half-life and duration of action).

[0290] (4) Excellent safety (lower toxicity and / or fewer side effects, wider therapeutic window), etc. DETAILED DESCRIPTION

[0291] Example

[0292] In order to make the purpose and technical scheme of the present invention clearer, the embodiments of the present invention are described in detail below in conjunction with examples. However, it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. In the examples, those without specifying specific conditions are all carried out according to normal conditions or the conditions recommended by the manufacturer. Those without specifying the manufacturer for reagents or instruments used are all conventional products that can be obtained commercially.

[0293] The structures of the compounds were determined by nuclear magnetic resonance ( 1 H NMR) or mass spectrometry (MS). 1 The H NMR was measured using a JEOL Eclipse 400 NMR spectrometer and the solvent was deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or hexadeuterated dimethyl sulfoxide (DMSO-d 6 ), the internal standard was tetramethylsilane (TMS), and the chemical shifts (δ) were given in parts per million (ppm).

[0294] The MS measuring instrument is Agilent (ESI) mass spectrometer, manufacturer: Agilent, model: Agilent 6120B.

[0295] Preparation method for high performance liquid chromatography:

[0296] Instrument model: Agilent 1260, chromatographic column: Waters SunFire Prep C18 OBD (19 mm × 150 mm × 5.0 μm); chromatographic column temperature: 25 ° C; flow rate: 20.0 mL / min; detection wavelength: 214 nm; elution gradient: (0 min: 10% A, 90% B; 16.0 min: 90% A, 10% B); mobile phase A: acetonitrile; mobile phase B: 0.05% formic acid aqueous solution or 0.05% ammonium bicarbonate aqueous solution.

[0297] Aluminum plates (20×20 cm) produced by Merck were used for thin layer chromatography silica gel plates (TLC), and the specifications used for thin layer chromatography separation and purification were GF 254 (1 mm) produced in Yantai.

[0298] The reaction is monitored by thin layer chromatography (TLC) or LC-MS; the developing solvent systems used include: dichloromethane and methanol system, n-hexane and ethyl acetate system, and petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound or adjusted by adding triethylamine.

[0299] The microwave reaction was carried out using a Biotage Initiator+ (400 W, RT-300° C.) microwave reactor.

[0300] Column chromatography generally uses 200-300 mesh silica gel as a carrier. The eluent system includes: dichloromethane and methanol system, and petroleum ether and ethyl acetate system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine can also be added for adjustment.

[0301] If not otherwise specified in the examples, the reaction temperature is room temperature (15°C to 30°C).

[0302] Unless otherwise specified, the reagents used in the examples were purchased from Acros Organics, Aldrich Chemical Company, Nanjing Yaoshi Technology, or Shanghai Shuya Pharmaceutical Technology.

[0303] The abbreviations used in this document have the following meanings:

[0304]

[0305]

[0306] Example 1: Preparation of 2-amino-5,6-dimethyl-1-{5-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl}-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 1)

[0307]

[0308] Step 1: Preparation of 4-bromo-2-fluoro-5-methylpyridine-3-carbaldehyde

[0309] 4-Bromo-2-fluoro-5-methylpyridine (10.8 g, 57 mmol) was placed in a reaction bottle, THF (80 mL) was added, and the dry ice acetone was cooled to -78°C. LDA (2M, 28.5 mL, 57 mmol) was slowly added, and the mixture was stirred and reacted for 1 h. Then DMF (4.16 g, 57 mmol) was added, and the mixture was reacted at -78°C for 1 h. After the reaction, the system was added to water (200 mL), and extracted with EA (100 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (5.5 g) was separated and purified by column chromatography (PE: EA = 5:1 elution) to obtain the title compound (5.5 g).

[0310] 1 H NMR (400 MHz, CDCl 3 ): δ10.37(s,1H),8.22(s,1H),2.45(s,3H)

[0311] Step 2: Preparation of 4-bromo-5-methyl-1H-pyrazolo[3,4-b]pyridine

[0312] 4-Bromo-2-fluoro-5-methylpyridine-3-carboxaldehyde (5.5 g, 25 mmol) was placed in a reaction bottle, THF (50 mL) was added, and then hydrazine hydrate (5 g, 100 mmol) was added, and the reaction was carried out at 60°C for 2 h. After the reaction was completed, the system was added to water (100 mL) and extracted with EA (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the crude title compound (5 g), which was directly used in the next step without further purification. MS m / z (ESI): 212.1 [M+H] + .

[0313] Step 3: Preparation of 4-bromo-5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridine

[0314] 4-Bromo-5-methyl-1H-pyrazolo[3,4-b]pyridine (5.00 g, 23.6 mmol) was placed in a reaction bottle, THF (50 mL) was added, and then p-toluenesulfonic acid (0.4 g, 2.36 mmol) and 2,3-dihydropyran (3.97 g, 47.2 mmol) were added, and the reaction was carried out at 25°C for 2 h. After the reaction was completed, the system was added to water (100 mL) and extracted with EA (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (1.40 g) was separated and purified by column chromatography (PE:EA=2:1 elution). MS m / z(ESI): 296.1[M+H] + Step 4: Preparation of N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1,1-diphenylmethanimine

[0315] 4-Bromo-5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridine (300 mg, 1.01 mmol) and benzophenone imine (551 mg, 3.04 mmol) were placed in a reaction flask, 1,4-dioxane (10 mL) was added, and Pd 2 (dba) 3 (186 mg, 203 μmol), Cs 2 CO 3 (990mg, 3.04mmol) and Xantphos (234mg, 405μmol), replace nitrogen three times, and react at 100℃ under nitrogen protection for 1h. After the reaction, add water (50mL) to the reaction system and extract with EA (30mLx 3), combine the organic phases and dry with anhydrous sodium sulfate, filter and evaporate the solvent under reduced pressure, separate and purify by column chromatography (PE:EA=6:1 elution) to obtain the title compound (300mg). MS m / z(ESI): 397.1[M+H] + .

[0316] 1 H NMR (400 MHz, DMSO-d 6 ): δ8.21(s,1H),7.96(s,1H),7.75(s,1H),7.23-7.62(m,9H),5.80-5.90(m,1H),3.88(d,J=11.6Hz,1H),3.5 4-3.70(m,1H),2.35-2.44(m,1H),2.17(s,3H),1.99(dd,J=7.4,4.8Hz,1H),1.67-1.83(m,2H),1.52(s,2H).

[0317] Step 5: Preparation of 5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine

[0318] Place N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1,1-diphenylmethanimine (210 mg, 530 μmol) in a reaction bottle, add MeOH (10 mL), then add 10% Pd / C (20 mg) and ammonium formate (333 mg, 5.3 mmol), and heat the reaction solution to 60°C for 12 h. After the reaction, filter the Pd / C with diatomaceous earth and wash with EA (20 mL x 3), evaporate the solvent under reduced pressure, and separate and purify by Prep-TLC (PE:EA=4:1) to obtain the title compound (120 mg). MS m / z(ESI): 233.1[M+H] + Step 6: Preparation of 3-bromo-5,6-dimethyl-N-[5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]pyridin-2-amine

[0319] 5-Methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (120 mg, 517 μmol) and 2,3-dibromo-5,6-dimethylpyridine (130 mg, 491 μmol) were placed in a reaction bottle, 1,4-dioxane (5 mL) was added, and Pd 2 (dba) 3 (47.3 mg, 51.7 μmol), Cs 2 CO 3 (505mg, 1.55mmol) and Xantphos (59.8mg, 103μmol), replace nitrogen three times, and react at 80℃ for 2h under nitrogen protection. After the reaction, add water (30mL) to the reaction system and extract with EA (30mL x 3). Combine the organic phases and dry them with anhydrous sodium sulfate. After filtering, evaporate the solvent under reduced pressure, separate and purify by Prep-TLC (DCM: MeOH = 10: 1 development) to obtain the title compound (210mg). MS m / z (ESI): 416.1 [M+H] + .

[0320] Step 7: Preparation of 2-amino-5,6-dimethyl-1-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0321] Malononitrile (60.0 mg, 908 μmol) was placed in a reaction bottle, 1,4-dioxane (5 mL) was added, and then potassium tert-butoxide (97.0 mg, 865 μmol) was added, and the nitrogen was replaced three times, and the reaction was carried out at 25 °C under nitrogen protection for 0.5 h. Then 3-bromo-5,6-dimethyl-N-[5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]pyridin-2-amine (180 mg, 432 μmol) and Pd(dppf)Cl were added. 2 (70.6 mg, 86.5 μmol), replaced nitrogen three times, reacted at 100 ° C for 2 h under nitrogen protection. After the reaction, water (30 mL) was added to the reaction system and extracted with EA (30 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate. After filtering, the solvent was evaporated under reduced pressure to obtain the crude title compound (160 mg), which was directly used in the next step without further purification. MS m / z (ESI): 402.2 [M+H] + .

[0322] Step 8: Preparation of 2-amino-5,6-dimethyl-1-{5-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl}-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

[0323] 2-Amino-5,6-dimethyl-1-[5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (100 mg, 249 μmol) was placed in a reaction bottle, concentrated sulfuric acid (2 mL) was added, and the reaction was heated to 50°C for 1 h. Then the system was added to ammonia water (10 mL) and reacted at 25°C for 1 h. After the reaction was completed, the reaction system was extracted with EA (30 mL x 3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (13 mg) was separated and purified by Prep-TLC (DCM: MeOH = 10: 1 development). MS m / z (ESI): 336.0 [M+H] + .

[0324] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.84(br,1H),8.64(s,1H),7.90(s,1H),7.66(s,1H),7.05(s,2H),6.74(br,2H),2.27(s,3H),2.20(s,3H),2.09(s,3H).

[0325] Example 2: Preparation of 2-amino-1-(7-fluoro-5-methyl-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 2)

[0326]

[0327] Step 1: Preparation of 2-bromo-5,6-difluoro-3-methylbenzaldehyde

[0328] The synthetic route of Example 1 was used to replace the first step reaction raw material 4-bromo-2-fluoro-5-methylpyridine with 1-bromo-4,5-difluoro-2-methylbenzene to obtain the title compound (2 g).

[0329] Step 2: Preparation of (E)-2-bromo-5,6-difluoro-3-methylbenzaldehyde-O-methyloxime

[0330] 2-Bromo-5,6-difluoro-3-methylbenzaldehyde (500 mg, 2.11 mmol), O-methylhydroxylamine (213 mg, 2.53 mmol), potassium carbonate (381 mg, 2.74 mmol) were placed in a reaction flask, DME (10 mL) was added, and the mixture was stirred at 25°C for 15 h. After the reaction was completed, the reaction system was poured into water for dilution, EA was added for extraction (30 mL x 3), the organic phases were combined and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain the crude title compound (500 mg), which was directly used in the next step without further purification. MS m / z (ESI): 264.1 [M+H] + .

[0331] Step 3: Preparation of 4-bromo-7-fluoro-5-methyl-1H-indazole

[0332] Place (E)-2-bromo-5,6-difluoro-3-methylbenzaldehyde-O-methyloxime (500 mg, 1.89 mmol) in a reaction bottle, add DME (8 mL), add hydrazine hydrate (1.2 g, 18.9 mmol) dropwise, raise the temperature to 90°C and stir for 12 h. Cool to room temperature, pour the reaction solution into ice water (20 mL) and stir for 10 min. Solid precipitates, filter, and dry the filter cake to obtain the crude title compound (420 mg), which is used directly in the next step without further purification. MS m / z (ESI): 229.0 [M+H] + .

[0333] Step 4: Preparation of 4-bromo-7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0334] The synthetic route of Example 1 was used to replace the raw material of the third step reaction, 4-bromo-5-methyl-1H-pyrazolo[3,4-b]pyridine, with 4-bromo-7-fluoro-5-methyl-1H-indazole to obtain the title compound (421 mg). MS m / z (ESI): 313.1 [M+H] + .

[0335] Step 5: Preparation of N-(7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1,1-diphenylmethanimine

[0336] The synthetic route of Example 1 was used to replace the raw material of the fourth step reaction, 4-bromo-5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridine, with 4-bromo-7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole to obtain the title compound (220 mg). MS m / z (ESI): 414.2 [M+H] + .

[0337] Step 6: Preparation of 7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0338] The synthetic route of Example 1 was used to replace the raw material of the fifth step reaction, N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1,1-diphenylmethanimine, with N-(7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1,1-diphenylmethanimine to obtain the title compound (110 mg). MS m / z (ESI): 250.1 [M+H] + .

[0339] Step 7: Preparation of N-(3-bromo-5,6-dimethylpyridin-2-yl)-7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0340] The synthetic route of Example 1 was used to replace the raw material of the sixth step reaction, 5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-amine, with 7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (141 mg). MS m / z (ESI): 433.2 [M+H] + .

[0341] Step 8: Preparation of 2-amino-1-(7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0342] The synthetic route of Example 1 was used to replace the raw material of the seventh step reaction, 3-bromo-5,6-dimethyl-N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]pyridin-2-amine, with N-(3-bromo-5,6-dimethylpyridin-2-yl)-7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (53 mg). MS m / z (ESI): 419.3 [M+H] + .

[0343] Step 9: Preparation of 2-amino-1-(7-fluoro-5-methyl-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

[0344] The synthetic route of Example 1 was used to replace 2-amino-1-(7-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile with 2-amino-5,6-dimethyl-1-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile to obtain the title compound (17 mg). MS m / z (ESI): 353.1 [M+H] + .

[0345] 1 H NMR (400 MHz, DMSO-d 6 )δ13.83(s,1H),7.88(s,1H),7.55(s,1H),7.34(d,J=11.6Hz,1H),6.88(s,2H),6.70(s,2H),2.27(s,3H),2.19(s,3H),2.00(s,3H).

[0346] Example 3: Preparation of 2-amino-1-(7-fluoro-5-methyl-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 3)

[0347]

[0348] Step 1: Preparation of 4-bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0349] The synthetic route of Example 1 was used to replace the raw material of the third step reaction, 4-bromo-5-methyl-1H-pyrazolo[3,4-b]pyridine, with 4-bromo-6-fluoro-1H-indazole to obtain the title compound (2 g). MS m / z (ESI): 299.0 [M+H] + .

[0350] Step 2: Preparation of 4-bromo-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole

[0351] 4-Bromo-6-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (0.8 g, 2.67 mmol) was placed in a reaction bottle, THF (10 mL) was added, and the dry ice acetone was cooled to -78°C. LDA (1.47 mL, 2M, 2.94 mmol) was slowly added, and the mixture was stirred and kept warm for 1 h. Then iodomethane (0.45 g, 3.2 mmol) was added, and the mixture was reacted at -78°C for 1 h. After the reaction, the system was added to water (100 mL), and extracted with EA (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (0.42 g) was obtained by separation and purification by Prep-HPLC. MS m / z (ESI): 313.0 [M+H] + .

[0352] Step 3: Preparation of N-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1,1-diphenylmethanimine

[0353] The synthetic route of Example 1 was used to replace the raw material of the fourth step reaction, 4-bromo-5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridine, with 4-bromo-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole to obtain the title compound (525 mg). MS m / z (ESI): 414.2 [M+H] + .

[0354] Step 4: Preparation of 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0355] The synthetic route of Example 1 was used to replace the raw material of the fifth step reaction, N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1,1-diphenylmethanimine, with N-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1,1-diphenylmethanimine to obtain the title compound (350 mg). MS m / z (ESI): 250.1 [M+H] + .

[0356] Step 5: Preparation of N-(3-bromo-5,6-dimethylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0357] The synthetic route of Example 1 was used to replace the raw material of the sixth step reaction, 5-methyl-1-(oxan-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-amine, with 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (303 mg). MS m / z (ESI): 433.2 [M+H] + .

[0358] Step 6: Preparation of 2-amino-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0359] The synthetic route of Example 1 was used to replace the raw material of the seventh step reaction, 3-bromo-5,6-dimethyl-N-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]pyridin-2-amine, with N-(3-bromo-5,6-dimethylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (247 mg). MSm / z(ESI): 419.2[M+H] + .

[0360] Step 7: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

[0361] The synthetic route of Example 1 was used to replace the raw material of the eighth step reaction, 2-amino-5,6-dimethyl-1-[5-methyl-1-(oxane-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile, with 2-amino-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile to obtain the title compound (21 mg). MS m / z (ESI): 353.1 [M+H] + .

[0362] 1 H NMR (400 MHz, DMSO-d 6 )δ13.35(s,1H),7.89(s,1H),7.57(d,J=9.6Hz,1H),7.48(s,1H),6.96(s,2H),6.73(s,2H),2.27(s,3H),2.20(s,3H),1.92(d,J=2.0Hz,3H).

[0363] Example 4: Preparation of 2-amino-1-(7-fluoro-5-methyl-1H-indazol-4-yl)-5,6-dimethyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 6)

[0364]

[0365] The title compound (14 mg) was obtained by a similar synthetic route as in Example 1. MS m / z (ESI): 373.1 [M+H] + .

[0366] 1 H NMR (400 MHz, DMSO-d 6 )δ13.64(s,1H),7.89(s,1H),7.87(dd,J=9.2,1.2Hz,1H),7.67(s,1H),7.10(s,2H),6.74(s,2H),2.27(s,3H),2.19(s,3H).

[0367] Example 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-morpholino-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 57)

[0368]

[0369] Step 1: Preparation of N-(3-bromo-5-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0370] Compound 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine (500 mg, 2.01 mmol), 2,3-dibromo-5-chloropyridine (762 mg, 2.81 mmol), Pd 2 (dba) 3 (184mg, 200μmol), Xantphos (232mg, 401μmol), Cs 2 CO 3 (1.96 g, 6.02 mmol) was placed in a reaction flask, and dioxane (15 mL) was added. The reaction was carried out at 100°C for 5 hours under nitrogen protection. After the reaction was completed, the reaction system was filtered and the solvent was evaporated under reduced pressure. The title compound (660 mg) was obtained by column chromatography separation and purification (PE / EA=5 / 1 elution). MS m / z (ESI): 441.1 [M+H] + .

[0371] Step 2: Preparation of 2-amino-5-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0372] Malononitrile (991 mg, 15.0 mmol) was placed in a reaction flask and DME (30 mL) was added. NaH (900 mg, 22.5 mmol, 60% purity) was added at room temperature. The reaction was carried out at 25°C for 0.5 hr. Then N-(3-bromo-5-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine (660 mg, 1.50 mmol) and Pd(dppf)Cl were added. 2 .CH 2 Cl 2 (1.23 g, 1.50 mmol). Replace nitrogen and react at 100°C for 2 hours. After the reaction, add the reaction system into water (60 mL), extract with EA (20 mL x 3), combine the organic phases and dry with anhydrous sodium sulfate, separate and purify by column chromatography (PE / EA=1:1 elution) to obtain the title compound (745 mg). MS m / z(ESI): 424.9[M+H] + .

[0373] Step 3: Preparation of tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0374] 2-Amino-5-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (745 mg, 1.75 mmol) and di-tert-butyl dicarbonate (1.15 g, 5.26 mmol) were placed in a reaction bottle, THF (20 mL) was added, and then DMAP (428 mg, 3.51 mmol) was added. The reaction was carried out at 50°C for 10 hours. After the reaction was completed, the solvent was evaporated from the reaction system under reduced pressure, and the title compound (400 mg) was obtained by column chromatography separation and purification (PE / EA=3 / elution). MS m / z(ESI): 525.2[M+H] + .

[0375] Step 4: Preparation of tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-morpholino-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0376] Tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (120 mg, 191.97 μmol) and morpholine (83.6 mg, 960 μmol) were placed in a reaction bottle, potassium carbonate (132 mg, 960 μmol), Pd 2 (dba) 3 (87.9 mg, 96.0 μmol), t-BuXphos (81.5 mg, 192 mmol), dioxane (15 mL). Replace nitrogen and react at 120 ° C for 6 hours. After the reaction, add the reaction system into water (30 mL), extract with EA (20 mL x 3), combine the organic phases and dry with anhydrous sodium sulfate, filter and evaporate the solvent under reduced pressure, and separate and purify by column chromatography (DCM / MeOH=10 / 1 elution) to obtain the title compound (40 mg). MS m / z (ESI): 576.3 [M+H] + .

[0377] Step 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-morpholino-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 57)

[0378] Tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-morpholino-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (40.0 mg, 69.5 μmol) was placed in a reaction bottle and concentrated sulfuric acid (4.0 mL) was added. The reaction was carried out at 25°C for 0.5 hr. After the reaction was completed, ammonia water (15 mL) was added dropwise to the reaction system at 0°C to adjust the pH to 10. The mixture was then extracted with EA (20 mL x 3), the solvent was evaporated under reduced pressure, and the title compound (1.42 mg) was obtained by separation and purification by Prep-HPLC. MS m / z (ESI): 410.2 [M+H] + .

[0379] 1 H NMR (400 MHz, CDCl 3 ): δ7.73(d,J=2.0Hz,1H),7.67(s,1H),7.35(d,J=8.8Hz,1H),7.30(d,J=2.0Hz,1H), 6.09(s,2H),5.47(s,2H),3.89-3.94(m,4H),3.15-3.20(m,4H),2.11(d,J=2.0Hz,3H)

[0380] Example 6: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 58)

[0381]

[0382] Step 1: Preparation of 2,3-dibromo-5-chloro-6-methylpyridine

[0383] 3-Bromo-5-chloro-6-methylpyridin-2-amine (4.50 g, 20.3 mmol) was placed in a reaction bottle, acetonitrile (30 mL) was added, the temperature was lowered to 0°C, and then cuprous bromide (5.83 g, 40.6 mmol) and tert-butyl nitrite (4.61 g, 44.70 mmol) were added, the nitrogen was replaced three times, and the reaction was carried out at 60°C for 3 hours under nitrogen protection. After the reaction, the system was added to water (200 mL), and extracted with EA (50 mL x 3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure, and the title compound (2.55 g) was obtained by column chromatography separation and purification (PE / EA=3 / 1 elution). MS m / z (ESI): 285.8 [M+H] + .

[0384] Step 2: Preparation of N-(3-bromo-5-chloro-6-methylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0385] 2,3-Dibromo-5-chloro-6-methylpyridine (1.60 g, 5.62 mmol) and 6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine (1.00 g, 4.01 mmol) were placed in a reaction flask, dioxane (20 mL) was added, and Pd 2 (dba) 3 (735mg, 802μmol), Cs 2 CO 3 (3.92g, 12.0mmol) and Xantphos (928mg, 1.60mmol), replace nitrogen three times, and react at 100℃ for 2hr under nitrogen protection. After the reaction, the solvent was directly evaporated under reduced pressure, and the title compound (1.40g) was obtained by column chromatography separation and purification (PE / EtOAc=5 / 1 elution). MS m / z(ESI): 455.0[M+H] + .

[0386] Step 3: Preparation of 2-amino-5-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0387] Using the synthetic route of Example 5, the second step reaction raw material N-(3-bromo-5-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine was replaced with N-(3-bromo-5-chloro-6-methylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (1.35 g). MS m / z (ESI): 439.1 [M+H] + .

[0388] Step 4: Preparation of tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0389] Using the synthetic route of Example 5, the raw material of the third step reaction, 2-amino-5-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile, was replaced with 2-amino-5-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile to obtain the title compound (1.36 g). MS m / z (ESI): 539.2 [M+H] + .

[0390] Step 5: Preparation of tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0391] Tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (100 mg, 186 μmol) was placed in a reaction bottle, dioxane (5 mL) was added, and then Pd 2 (dba) 3 (85.0mg, 92.8μmol), t-Bu-Xphos (78mg, 186μmol) and sodium methoxide (5.4M in MeOH, 172μL), replace nitrogen three times, react at 120℃ for 2hr under nitrogen protection. After the reaction, add water (30mL) to the reaction system and extract with EA (20mL x 3), combine the organic phases and dry with anhydrous sodium sulfate, filter and evaporate the solvent under reduced pressure, separate and purify by column chromatography (PE / EA=4 / 1 elution) to obtain the title compound (60mg). MS m / z(ESI): 535.2[M+H] + .

[0392] Step 6: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide

[0393] Using the synthetic route of Example 5, the raw material of the fifth step reaction, tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(4-methylpiperazine-1)-yl)-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate, was replaced with tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-methoxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (1.41 mg). MS m / z (ESI): 369.1 [M+H] + .

[0394] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.31(s,1H),7.67(s,1H),7.56(d,J=9.6Hz,1H),7.48(s,1H),6.96(s,2H),6.83(s,2H),3.88(s,3H),2.14(s,3H),1.92(d,J=2.0Hz,3H).

[0395] Example 7: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 59)

[0396]

[0397] Step 1: Preparation of tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0398] Tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (350 mg, 649 μmol) was placed in a reaction bottle, dioxane (8 mL) and H 2 O (4 mL), Pd 2 (dba) 3(119 mg, 130 μmol), KOH (182 mg, 3.25 mmol) and t-Bu-Xphos (110 mg, 260 μmol), replace nitrogen three times, and react at 100 ° C for 2 hours under nitrogen protection. After the reaction, water (50 mL) was added to the reaction system and extracted with EA (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under reduced pressure, and the title compound (310 mg) was separated and purified by column chromatography (PE / EA=3 / 1 elution). MS m / z (ESI): 521.2 [M+H] + .

[0399] Step 2: Preparation of tert-butyl(tert-butoxycarbonyl)(5-((tert-butoxycarbonyl)oxy)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0400] Tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (310 mg, 596 μmol) was placed in a reaction bottle, THF (10 mL) was added, followed by TEA (301 mg, 2.98 mmol), DMAP (182 mg, 1.49 mmol) and di-tert-butyl dicarbonate (650 mg, 2.98 mmol), and the mixture was reacted at 60°C for 2 hours. After the reaction was completed, water (30 mL) was added to the reaction system and extracted with EA (30 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the crude title compound (400 mg), which was directly used in the next step. MS m / z (ESI): 721.3 [M+H] + .

[0401] Step 3: Preparation of tert-butyl(tert-butoxycarbonyl)(3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0402] Tert-butyl (tert-butoxycarbonyl)(5-((tert-butoxycarbonyl)oxy)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (400 mg, 555 μmol) was placed in a reaction bottle, THF (3 mL) was added, and H2 O (3mL) and MeOH (3mL), then add lithium hydroxide (20mg, 477μmol), and react at 25℃ for 1hr. After the reaction, adjust the reaction system to Ph=4 with 1M dilute hydrochloric acid, and extract with EA (20mL x 3), combine the organic phases and dry with anhydrous sodium sulfate, filter and evaporate the solvent under reduced pressure, separate and purify by column chromatography (PE / EA=3 / 1 elution) to obtain the title compound (110mg). MS m / z (ESI): 621.2 [M+H] + .

[0403] Step 4: Preparation of tert-butyl(tert-butoxycarbonyl)(3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0404] Tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (110 mg, 177 μmol) was placed in a reaction bottle, DMF (5 mL) was added, and then isopropyl bromide (218 mg, 1.77 mmol) and potassium bicarbonate (177 mg, 1.77 mmol) were added, and the reaction was carried out at 25°C for 2 hours. After the reaction was completed, water (30 mL) was added to the reaction system and extracted with EA (30 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (50 mg) was separated and purified by column chromatography (PE / EA=5 / 1). MS m / z (ESI): 663.2 [M+H] + .

[0405] Step 5: Preparation of tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0406] Tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (45.0 mg, 67.9 μmol) was placed in a reaction bottle, DMSO (2 mL) was added, followed by potassium carbonate (28.2 mg, 204 μmol) and hydrogen peroxide (118 mg, 3.47 mmol), and the mixture was reacted at 25°C for 12 hours. After the reaction was completed, water (10 mL) was added to the reaction system and extracted with EA (10 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain a crude compound (25 mg), which was directly used in the next step. MS m / z (ESI): 581.3 [M+H] + .

[0407] Step 6: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 59)

[0408] Tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (25 mg, 43.1 μmol) was placed in a reaction bottle, added to a 2M hydrochloric acid 1,4-dioxane solution (5 mL), and reacted at 25°C for 2 hours. After the reaction was completed, the solvent was directly evaporated under reduced pressure, and the title compound (3.05 mg) was separated and purified by Prep-HPLC. MS m / z (ESI): 397.2 [M+H] + .

[0409] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.31(s,1H),7.71(s,1H),7.56(d,J=9.6Hz,1H),7.49(s,1H),6.98(s,2H),6.79(s,2H) ,4.70(dd,J=12.0,6.0Hz,1H),2.13(s,3H),1.93(d,J=1.6Hz,3H),1.28(s,3H),1.27(s,3H).

[0410] Example 8: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 60)

[0411]

[0412] Step 1: Preparation of tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0413] Tert-butyl (5-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate (200 mg, 371 μmol) was placed in a reaction bottle, dioxane (10 mL) and H 2 O (2mL), 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborinane (312mg, 1.86mmol), t-BuXPhos-Pd-G3 (147mg, 185μmol) and potassium carbonate (154mg, 1.11mmol) were added in sequence, nitrogen was replaced three times, and the reaction was carried out at 120℃ for 2hr under nitrogen protection. After the reaction, water (50mL) was added to the reaction system and extracted with EA (20mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under reduced pressure, and the title compound (200mg) was separated and purified by column chromatography (PE / EA=5 / 1 elution). MS m / z(ESI): 545.3[M+H] + .

[0414] Step 2: Preparation of tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0415] Tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (190 mg, 349 μmol) was placed in a reaction bottle, MeOH (7 mL) and DCM (7 mL) were added, the temperature was reduced to -78 ° C, and then ozone was introduced, and the reaction was carried out at -78 ° C for 0.5 hr; then the temperature was raised to 0 ° C, nitrogen was replaced three times, sodium borohydride (212 mg, 5.61 mmol) was slowly added in batches, and the reaction was carried out at 0 ° C for 0.5 hr under nitrogen protection. After the reaction was completed, water (50 mL) was added to the reaction system and extracted with DCM (20 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (85 mg) was separated and purified by column chromatography (PE / EA=2 / 1). MS m / z (ESI): 549.3 [M+H] + .

[0416] Step 3: Preparation of tert-butyl(tert-butoxycarbonyl)(5-(2-((tert-butoxycarbonyl)oxy)ethyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2)-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0417] Using the synthetic route of Example 7, the second step reaction raw material tert-butyl (3-cyano-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -5-hydroxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate was replaced with tert-butyl (3-cyano-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -5- (2-hydroxyethyl) -6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (20 mg). MS m / z (ESI): 749.4 [M + H] + .

[0418] Step 4: Preparation of tert-butyl (5-(2-((tert-butoxycarbonyl)oxy)ethyl)-3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0419] Using the synthetic route of Example 7, the raw material of the fifth step reaction, tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate, was replaced with tert-butyl (tert-butoxycarbonyl) (5-(2-((tert-butoxycarbonyl)oxy)ethyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2)-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (15 mg). MS m / z (ESI): 667.3 [M+H] + .

[0420] Step 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 60)

[0421] Using the synthetic route of Example 7, the raw material of the sixth step, tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate, was replaced with tert-butyl (5-(2-((tert-butoxycarbonyl)oxy)ethyl)-3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate to obtain the title compound (5 mg). MS m / z (ESI): 383.2 [M+H] + .

[0422] 1 H NMR (400MHz DMSO-d 6 ): δ13.32(s,1H),7.86(s,1H),7.56(d,J=9.6Hz,1H),7.48(s,1H),6.95(s,2H),6.72(s,2H),4.6 5(t,J=5.2Hz,1H),3.60-3.65(m,2H),2.78(t,J=7.2Hz,2H),2.25(s,3H),1.92(d,J=2.0Hz,3H).

[0423] Example 9: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(hydroxymethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 61)

[0424]

[0425] The title compound (5 mg) was obtained by a similar synthetic route as in Example 8. MS m / z (ESI): 369.1 [M+H] + .

[0426] 1 H NMR (400MHz DMSO-d 6 ): δ13.35(s,1H),7.99(s,1H),7.58(d,J=9.6Hz,1H),7.48(s,1H),6.96(s,2H),6.71(s ,2H),4.94(t,J=5.2Hz,1H),4.53(d,J=4.4Hz,2H),2.27(s,3H),1.92(d,J=2.0Hz,3H).

[0427] Example 10: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(2-methoxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 62)

[0428]

[0429] Step 1: Preparation of tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)(tert-butoxycarbonyl)carbamate

[0430] Using the synthetic route of Example 7, the second step reaction raw material tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate was replaced with tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (200 mg). MS m / z (ESI): 645.3 [M+H] + .

[0431] Step 2: Preparation of tert-butyl(tert-butoxycarbonyl)(3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0432] The synthetic route of Example 8 was used to replace the second step reaction raw material tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate with tert-butyl (5-allyl-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) (tert-butoxycarbonyl) carbamate to obtain the title compound (200 mg). MS m / z (ESI): 649.3 [M+H] + .

[0433] Step 3: Preparation of tert-butyl(tert-butoxycarbonyl)(3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-methoxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0434] Tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-hydroxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (100 mg, 154 μmol) was placed in a reaction bottle, DCM (5 mL) was added, and then silver oxide (357 mg, 1.54 mmol) and iodomethane (219 mg, 1.54 mmol) were added, and the reaction was carried out at 40°C for 1 hr. After the reaction was completed, silica gel was applied and filtered, and the solvent was evaporated under reduced pressure to obtain the crude title compound (110 mg), which was directly used in the next step. MS m / z (ESI): 663.3 [M+H] + .

[0435] Step 4: Preparation of tert-butyl(tert-butoxycarbonyl)(3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-methoxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0436] Using the synthetic route of Example 7, the raw material of the fifth step reaction, tert-butyl (tert-butoxycarbonyl) (3-cyano-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -5-isopropoxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate, was replaced with tert-butyl (tert-butoxycarbonyl) (3-cyano-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -5- (2-methoxyethyl) -6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (15 mg). MS m / z (ESI): 681.3 [M+H] + .

[0437] Step 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(2-methoxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 62)

[0438] Using the synthetic route of Example 7, the raw material of the sixth step, tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate, was replaced with tert-butyl (tert-butoxycarbonyl) (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(2-methoxyethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate to obtain the title compound (6 mg). MS m / z (ESI): 397.2 [M+H] + .

[0439] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.33(s,1H),7.89(s,1H),7.57(d,J=9.6Hz,1H),7.49(s,1H),6.97(s,2H),6.74(s,2H), 3.55(t,J=7.2Hz,2H),3.28(s,3H),2.85(t,J=7.2Hz,2H),2.25(s,3H),1.92(d,J=2.0Hz,3H)

[0440] Example 11: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-(methoxymethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 63)

[0441]

[0442] The title compound (10 mg) was obtained by a similar synthetic route as in Example 10. MS m / z (ESI): 383.2 [M+H] + .

[0443] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.34(s,1H),8.01(s,1H),7.58(d,J=9.6Hz,1H),7.50(s,1H),7.00(s,2 H),6.76(s,2H),4.44(s,2H),3.31(s,3H),2.26(s,3H),1.93(d,J=2.0Hz,3H)

[0444] Example 12: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-4-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 64)

[0445]

[0446] Step 1: Preparation of 2-bromo-4-methoxy-6-methyl-3-nitropyridine

[0447] 2,4-Dibromo-6-methyl-3-nitropyridine (1.00 g, 3.38 mmol) was placed in a reaction bottle, MeOH (5 mL) was added, and then sodium methoxide solution (5.4 M, 626 μL) was added, and the mixture was heated to 60°C for 1 hour. After the reaction was completed, the reaction system was added to water (100 mL), and extracted with EA (50 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (600 mg) was separated and purified by column chromatography (PE / EA=5 / 1). MS m / z (ESI): 247.0 [M+H] + .

[0448] Step 2: Preparation of 2-bromo-4-methoxy-6-methylpyridin-3-amine

[0449] 2-Bromo-4-methoxy-6-methyl-3-nitropyridine (590 mg, 2.39 mmol) was placed in a reaction flask, and EtOH (12 mL) and H 2O (3mL), then add iron powder (2.00g, 35.8mmol) and ammonium chloride (2.30g, 43.0mmol), heat to 80℃ and react for 2hr. After the reaction, filter through silica gel pad, extract with EA (30mL x 3), combine the organic phases and dry with anhydrous sodium sulfate, filter and evaporate the solvent under reduced pressure to obtain a crude compound (510mg), which is directly used in the next reaction. MS m / z (ESI): 217.0 [M+H] + .

[0450] Step 3: Preparation of 2,3-dibromo-4-methoxy-6-methylpyridine

[0451] 2-Bromo-4-methoxy-6-methylpyridin-3-amine (500 mg, 2.30 mmol) was placed in a reaction bottle, acetonitrile (10 mL) was added, and then cuprous bromide (661 mg, 4.61 mmol) and tert-butyl nitrite (594 mg, 5.07 mmol) were added, and the mixture was heated to 60°C for 1 hour. After the reaction, the system was added to water (50 mL) and extracted with EA (30 mL x 3). The organic phases were combined and dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The title compound (320 mg) was separated and purified by column chromatography (PE / EA=6 / 1). MS m / z (ESI): 281.9 [M+H] + .

[0452] Step 4: Preparation of N-(3-bromo-4-methoxy-6-methylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0453] The synthetic route of Example 6 was used to replace the second step reaction raw material 2,3-dibromo-5-chloro-6-methylpyridine with 2,3-dibromo-4-methoxy-6-methylpyridine to obtain the title compound (120 mg). MS m / z (ESI): 451.1 [M+H] + .

[0454] Step 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-4-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0455] The synthetic route of Example 5 was used to replace the second step reaction raw material N-(3-bromo-5-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine with N-(3-bromo-4-methoxy-6-methylpyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (120 mg). MSm / z(ESI):435.1[M+H] + .

[0456] Step 6: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-4-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 64)

[0457] Using the synthetic route of Example 5, the raw material of the fifth step reaction, tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(4-methylpiperazine-1)-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate, was replaced with 2-amino-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-4-methoxy-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile to obtain the title compound (3 mg). MS m / z (ESI): 369.1 [M+H] + .

[0458] 1 H NMR (400 MHz, DMSO-d 6 ):δ13.19-13.55 (m, 1H), 7.72-7.82 (m, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.50 (s, 1H), 7.04 (s, 2H), 6.79 (d, J = 3.2 Hz, 1H), 6.72 (s, 1H), 4.00 (s, 3H), 2.25 (s, 3H), 1.91 (s, 3H). Example 13: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-((2-hydroxyethoxy)methyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 65)

[0459]

[0460] Step 1: Preparation of methyl tert-butyl (5-(bromomethyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-1H-pyrrolo[2,3-b]pyridin-2-yl)(tert-butoxycarbonyl)carbamate

[0461] Tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-(hydroxymethyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (300 mg, 472 μmol) was dissolved in DCM (12.0 mL) and placed in a reaction bottle, and then triphenylphosphine (247 mg, 945 μmol) and N-bromosuccinimide (168 mg, 945 μmol) were added and reacted at 25°C for 3 hours. After the reaction was completed, the reaction system was added to water (100 mL), extracted with DCM (20 x 3 mL), the organic phases were combined and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under reduced pressure, and the title compound (60 mg) was obtained by column purification (PE / EA=5 / 1 elution). MS m / z(ESI):699.1[M+H] + .

[0462] Step 2: Preparation of tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0463] Sodium hydride (8.73 mg, 1.22 mmol, 60% purity) was dissolved in DMF (4 mL) and placed in a reaction bottle. 2-(tert-butoxy)1-ethanol (86.4 mg, 731 μmol) was added and reacted at 25°C for 0.5 hr. Then tert-butyl(5-(bromomethyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-1H-pyrrolo[2,3-b]pyridin-2-yl)(tert-butoxycarbonyl)carbamic acid methyl ester (170 mg, 243 μmol) was added and reacted at 25°C for 2 hr. After the reaction was completed, the reaction system was added to water (20 mL), extracted with EA (20 x 3 mL), the organic phases were combined and dried with anhydrous sulfuric acid, and the solvent was evaporated from the filtrate under reduced pressure to obtain the crude title compound (205 mg). MS m / z(ESI):635.3[M+H] + .

[0464] Step 3: Preparation of tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)(tert-butoxycarbonyl)carbamate

[0465] The synthetic route of Example 7 was used to replace the second step reaction raw material tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate with tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate to obtain the title compound (100 mg). MS m / z (ESI): 735.4 [M+H] + .

[0466] Step 4: Preparation of tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0467] Using the synthetic route of Example 7, the raw material of the fifth step reaction, tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate, was replaced with tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) (tert-butoxycarbonyl) carbamate to obtain the title compound (100 mg). MS m / z (ESI): 653.3 [M+H] + .

[0468] Step 5: Preparation of 2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-5-((2-hydroxyethoxy)methyl)-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 65)

[0469] Using the synthetic route of Example 7, the raw material of the sixth step, tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate, was replaced with tert-butyl (5-((2-(tert-butoxy)ethoxy)methyl)-3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate to obtain the title compound (2 mg). MS m / z (ESI): 413.2 [M+H] +

[0470] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.34-13.40(m,1H),8.03(s,1H),7.58(d,J=9.6Hz,1H),7.49(s,1H),7.00(s,2H),6.76(s,2H),4 .61-4.68(m,1H),4.52(s,2H),3.53(s,2H),3.50(d,J=4.8Hz,2H),2.27(s,3H),1.92(d,J=2.0Hz,3H)

[0471] Example 14: Preparation of (R)-2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-6-(3-(methylamino)pyrrolidin-1-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 66)

[0472]

[0473] Step 1: Preparation of N-(3-bromo-6-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine

[0474] The synthetic route of Example 6 was used to replace the second step reaction raw material 2,3-dibromo-5-chloro-6-methylpyridine with 2,3-dibromo-6-chloropyridine to obtain the title compound (400 mg). MS m / z (ESI): 441.1 [M+H] + .

[0475] Step 2: Preparation of 2-amino-6-chloro-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile

[0476] The synthetic route of Example 5 was used to replace the second step reaction raw material N-(3-bromo-5-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine with N-(3-bromo-6-chloropyridin-2-yl)-6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-amine to obtain the title compound (350 mg). MS m / z (ESI): 425.1 [M+H] + .

[0477] Step 3: Preparation of tert-butyl(tert-butoxycarbonyl)(6-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0478] Using the synthetic route of Example 7, the second step reaction raw material tert-butyl (3-cyano-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -5-hydroxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate was replaced with 2-amino-6-chloro-1- (6-fluoro-5-methyl-1- (tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -1H-pyrrolo [2,3-b] pyridine-3-carbonitrile to obtain the title compound (300 mg). MS m / z (ESI): 625.2 [M + H] + .

[0479] Step 4: Preparation of tert-butyl ((3R)-1-(2-((tert-butoxycarbonyl)amino)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl))-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrrolidin-3-yl)(methyl)carbamate

[0480] Tert-butyl (tert-butoxycarbonyl) (6-chloro-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl) carbamate (575 mg, 1.10 mmol) and (R)-methyl (pyrrolidin-3-yl) carbamic acid tert-butyl ester (438 mg, 2.19 mmol) were dissolved in dioxane (8 mL) and placed in a reaction flask. Pd was added. 2 (dba) 3(401 mg, 438 μmol), cesium carbonate (1.07 g, 3.29 mmol) and RuPhos (409 mg, 876 μmol), heated to 100 ° C for 12 hours. After the reaction, the reaction system was added to water (30 mL), then extracted with EA (20 mL x 3), the organic phases were combined and dried over anhydrous sodium sulfate, filtered and the solvent was evaporated under reduced pressure, and the title compound (620 mg) was obtained by column purification (PE / EA = 4 / 1 elution). MS m / z (ESI): 689.3 [M+H] + .

[0481] Step 5: Preparation of tert-butyl(tert-butoxycarbonyl)(6-((R)-3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-3-cyano-1-(6-fluoro-5-methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0482] The synthetic route of Example 7 was used to replace the second step reaction raw material tert-butyl (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-hydroxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate with tert-butyl ((3R)-1-(2-((tert-butoxycarbonyl)amino)-3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl))-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrrolidin-3-yl)(methyl)carbamate to obtain the title compound (100 mg). MS m / z (ESI): 789.4 [M+H] + .

[0483] Step 6: Preparation of tert-butyl(tert-butoxycarbonyl)(6-((R)-3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-3-carbamoyl-1-(6-fluoro-5-methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate

[0484] Using the synthetic route of Example 7, the raw material of the fifth step, tert-butyl (tert-butoxycarbonyl) (3-cyano-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate, was replaced with tert-butyl (tert-butoxycarbonyl) (6-((R)-3-((tert-butoxycarbonyl) (methyl) amino) pyrrolidin-1-yl) -3-cyano-1-(6-fluoro-5-methyl) -1-(tetrahydro-2H-pyran-2-yl) -1H-indazol-4-yl) -1H-pyrrolo [2,3-b] pyridin-2-yl) carbamate to obtain the title compound (45 mg). MS m / z (ESI): 807.4 [M+H] + .

[0485] Step 7: Preparation of (R)-2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-6-(3-(methylamino)pyrrolidin-1-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 66)

[0486] The synthetic route of Example 7 was used to replace the raw material of the sixth step reaction, tert-butyl (3-carbamoyl-1-(6-fluoro-5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-5-isopropoxy-6-methyl-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate, with tert-butyl (tert-butoxycarbonyl) (6-((R)-3-((tert-butoxycarbonyl)(methyl)amino)pyrrolidin-1-yl)-3-carbamoyl-1-(6-fluoro-5-methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)carbamate to obtain the title compound (5 mg). MS m / z (ESI): 423.2 [M+H] +

[0487] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.25-13.39(m,1H),8.27(s,1H),7.93(d,J=8.4Hz,1H),7.50-7.55(m,2H),6.68(s,2H),6.63(s,2H),6.20(d,J=8.0Hz, 1H),3.16-3.24(m,3H),3.07-3.15(m,2H),2.97-3.03(m,1H),2.28(d,J=3.6Hz,3H),1.99(d,J=1.6Hz,3H),1.68-1.76(m,1H)

[0488] Example 15: Preparation of (S)-2-amino-1-(6-fluoro-5-methyl-1H-indazol-4-yl)-6-(3-(methylamino)pyrrolidin-1-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Compound 67)

[0489]

[0490] The target compound was obtained by a similar synthetic route as in Example 14. MS m / z (ESI): 423.2 [M+H] +

[0491] 1 H NMR (400 MHz, DMSO-d 6 ): δ13.20-13.42(m,1H),8.29(s,1H),7.93(d,J=8.4Hz,1H),7.50-7.56(m,2H),6.61-6.71(m,4H),6.20(d,J=8.4Hz ,1H),3.19-3.26(m,3H),3.07-3.16(m,2H),2.95-3.02(m,1H),2.27(s,3H),1.99(d,J=1.6Hz,3H),1.66-1.77(m,1H)

[0492] Biological evaluation

[0493] Experimental example: Test of the inhibitory effect of compounds on PKMYT1 enzyme activity

[0494] 1. Test system

[0495] Enzyme: PKMYT1 (purchased from Carna, 05-176)

[0496] Substrate: Unactive CDK1 (purchased from Signalchem, C22-14G)

[0497] ATP, ADP-Glo ​​Reagent, Detection Solution: all from ADP-Glo ​​Kinase Assay Kit (Promega, V9101) 2. Experimental steps

[0498] Add 60 μL of 100 μM compound to the 384-well dilution plate, and dilute it 10-fold with DMSO to three concentration points, namely 10, 1, and 0.1 μM. Use an Echo sonic pipette to transfer 0.1 μL of the diluted compound solution to the 384-well detection plate, with 2 replicates for each concentration. Add 5 μL of PKMYT1 enzyme working solution to the 384-well detection plate, centrifuge at 1000 rpm for 1 min, incubate with the compound at 25°C for 10 minutes, then add 5 μL of Substrate&ATP working solution, incubate at 25°C for 180 minutes, and react. Add 5 μL of ADP-Glo ​​Reagent to the 384-well detection plate, centrifuge at 1000 rpm for 1 min, and incubate at 25°C for 40 minutes. Finally, add 10 μL of Detection Solution to the 384-well plate, centrifuge at 1000 rpm for 1 min, incubate at 25°C for 40 minutes, and read the chemiluminescent signal using a BMG microplate reader. The solvent group (DMSO) was used as the negative control, and the buffer group (without PKMYT1 enzyme) was used as the blank control. The relative inhibitory activity percentage (i.e., inhibition rate) of compounds at different concentrations was calculated according to the following formula:

[0499] Relative inhibitory activity percentage = (1-(different concentration compound groups-blank control) / (negative control-blank control))*100%

[0500] The relative inhibitory activity percentages of compounds at different concentrations were plotted against compound concentrations, and the curves were fitted according to the four-parameter model to calculate the IC 50 value:

[0501] y=min+(max-min) / (1+(x / IC 50 )^(-Hillslope))

[0502] Wherein y is the relative inhibitory activity percentage, max and min are the maximum and minimum values ​​of the fitting curve, respectively, x is the logarithmic concentration of the compound, and Hillslope is the slope of the curve. The inhibitory effect of the compound on the PKMYT1 enzyme was determined according to the above method, and the results are shown in Table 1.

[0503] Table 1. Inhibitory activity of the compounds of the present invention on PKMYT1

[0504]

[0505]

[0506] The experimental results show that the compound of the present invention has a strong inhibitory effect on the PKMYT1 enzyme.

[0507] In summary, the compounds provided by the present invention are highly active PKMYT1 inhibitors with novel structures, and have great potential to be developed into drugs for treating diseases or conditions related to PKMYT1 activity.

[0508] In addition to those embodiments described herein, various modifications of the present invention will be apparent to those skilled in the art based on the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books and any other disclosures) is incorporated herein by reference in its entirety.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable form thereof: in: X and Z are each independently selected from N or CR 2A ; R 1 , R 2 and each R 2A are independently selected from hydrogen, halogen, hydroxyl, oxo, -CN, -NO2, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -O(4-6 membered heterocycloalkyl), -S(C 1-6 Alkyl), -NR x R y , -C(O)NH2, -C(O)(4-6 membered heterocycloalkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 Cycloalkyl), -C(O)NH(4-6 membered heterocycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2NR x R y , C 6-10 aryl and 5-10 membered heteroaryl; or R 1 Same as the adjacent R 2 or R 2A Together they form C 3-6 Alkylene; the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; R 3 Selected from hydrogen, halogen, C 1-6 Alkyl, C 3-4 Cycloalkyl or C 1-6 Haloalkyl; R 4 and R 5 are each independently selected from hydrogen, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl; R x and R y are each independently selected from hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)(C 1-6 alkyl), -C(O)(C 3-6 Cycloalkyl), -C(O)(4-6 membered heterocycloalkyl), -C(O)O(C 1-6 alkyl), -C(O)O(C 3-6 Cycloalkyl), -C(O)O(4-6 membered heterocycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2(C 3-6 cycloalkyl) and -S(O)2(4-6 membered heterocycloalkyl); the alkyl, cycloalkyl or heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, hydroxyl, oxo, -CN, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NH2, -NH(C 1-6 Alkyl), -NH(C 1-6 alkyl)2 and 4-6 membered heterocycloalkyl substituents; The pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.

2. The compound according to claim 1 or a pharmaceutically acceptable form thereof, wherein: X and Z are each independently selected from N or CR 2A ; R 1 , R 2 and each R 2A are independently selected from hydrogen, halogen, hydroxyl, oxo, -CN, -NO2, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -O(4-6 membered heterocycloalkyl), -S(C 1-6 Alkyl), -NR x R y , -C(O)NH2, -C(O)(4-6 membered heterocycloalkyl), -C(O)NH(C 1-6 alkyl), -C(O)NH(C 3-6 Cycloalkyl), -C(O)NH(4-6 membered heterocycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2NR x R y , C 6-10 aryl and 5-10 membered heteroaryl; or R 1 Same as the adjacent R 2 or R 2A Together they form C 3-6 Alkylene; the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; R 3 Selected from hydrogen, halogen, C 1-6 Alkyl, C 3-4 Cycloalkyl or C 1-6 Haloalkyl; R 4 and R 5 are each independently selected from hydrogen, halogen, C 1-6 Alkyl or C 1-6 Haloalkyl; R x and R y are each independently selected from hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl, -C(O)(C 1-6 alkyl), -C(O)(C 3-6 Cycloalkyl), -C(O)(4-6 membered heterocycloalkyl), -C(O)O(C 1-6 alkyl), -C(O)O(C 3-6 Cycloalkyl), -C(O)O(4-6 membered heterocycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2(C 3-6 cycloalkyl) and -S(O)2(4-6 membered heterocycloalkyl); the alkyl, cycloalkyl or heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, hydroxyl, oxo, -CN, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NH2, -NH(C 1-6 Alkyl), -NH(C 1-6 alkyl)2 and 4-6 membered heterocycloalkyl substituents.

3. A compound according to claim 1 or 2, or a pharmaceutically acceptable form thereof, wherein: X is selected from N and CH.

4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable form thereof, wherein: Z is selected from N and -CH; Preferably, X is selected from N, and Z is selected from N; X is selected from N, and Z is selected from CH; X is selected from CH, and Z is selected from N; or X is selected from CH, and Z is selected from CH.

5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable form thereof, wherein: R 1 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 3-10 membered heterocycloalkyl (preferably 4-8 membered heterocycloalkyl), -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 1 Selected from hydrogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -C 1-4 Alkyl-OC 1-4 Alkyl-OH, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl) and -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl; the heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl -OH and -NR x R y Substituents are substituted; More preferably, R 1 is selected from hydrogen, methyl, isopropyl, difluoromethyl, trifluoromethyl, cyclopropyl, Methoxy, 6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable form thereof, wherein: R 1 Selected from halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 1 Selected from -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl), -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl; More preferably, R 1 is selected from methyl, isopropyl, difluoromethyl, cyclopropyl, 7. A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable form thereof, wherein: R 2 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 3-6 Cycloalkyl), -S(O)2(C 1-4 Alkyl) and -S(O)2NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 Alkyl; the heterocycloalkyl is optionally substituted by one or more independently selected from deuterium, halogen, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl) and -NR x R y Substituents are substituted; More preferably, R 2 is selected from hydrogen, halogen, methyl, isopropyl, fluoromethyl, trifluoromethyl, -SO2CH3, -SO2N(CH3)2, -CH2OCH3, 8. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable form thereof, wherein: R 2 Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-6 Alkyl), -O(C 3-6 Cycloalkyl), -S(O)2(C 1-6 Alkyl), -S(O)2NR x R y , the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, -O(C 3-6 Cycloalkyl), -S(O)2(C 1-4 Alkyl) and -S(O)2NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 alkyl; More preferably, R 2 Selected from hydrogen, halogen, methyl, isopropyl, fluoromethyl, -SO2CH3, -SO2N(CH3)2, -CH2OCH3.

9. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable form thereof, wherein: R 2A Selected from hydrogen, halogen, hydroxyl, -C 1-6 Alkyl and -O(C 1-6 alkyl), the alkyl being optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 2A Selected from hydrogen and -O(C 1-4 alkyl); More preferably, R 2A is selected from hydrogen and methoxy.

10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable form thereof, wherein: R 3 Selected from hydrogen, halogen and -C 1-6 Alkyl, each of which is optionally substituted by one or more independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -NR x R y , -C 3-6 Substitution of cycloalkyl and 4-6 membered heterocycloalkyl substituents; Preferably, R 3 Selected from hydrogen, halogen, -C 1-4 Alkyl and -C 1-4 Haloalkyl; More preferably, R 3 is selected from the group consisting of hydrogen, fluorine, chlorine, methyl, difluoromethyl and trifluoromethyl.

11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable form thereof, wherein: R 4 Selected from hydrogen, halogen, -C 1-4 Alkyl and -C 1-4 Preferably, R 4 Selected from hydrogen and fluorine.

12. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable form thereof, wherein: R 5 Selected from hydrogen, halogen, -C 1-4 Alkyl and -C 1-4 Preferably, R 5 Selected from hydrogen and fluorine.

13. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable form thereof, wherein: The compound represented by formula (I) is a compound represented by the following formula (IA): Alternatively, the compound represented by formula (I) is a compound represented by the following formula (II): Preferably, the compound represented by formula (II) is a compound represented by the following formula (IIA): Preferably, the compound represented by formula (II) is a compound represented by the following formula (III): Preferably, the compound represented by formula (III) is a compound represented by the following formula (IIIA):

14. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable form thereof, wherein: The compound represented by formula (I) is a compound represented by the following formula (IV): Preferably, in the compound of formula (IV), R 1 Selected from hydrogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl-OH, -C 1-4 Alkyl-OC 1-4 Alkyl, -C 1-4 Alkyl-OC 1-4 Alkyl-OH, -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 1-4 Alkyl), -O(C 3-6 Cycloalkyl) and -NR x R y , R x and R y Each independently selected from C 1-6 Alkyl, C 3-8 Cycloalkyl; R 2 Selected from hydrogen, halogen, -C 1-4 Alkyl, -C 1-4 Haloalkyl, -C 1-4 Alkyl O(C 1-4 Alkyl), -C 3-6 Cycloalkyl, 4-6 membered heterocycloalkyl, -O(C 3-6 Cycloalkyl), -S(O)2(C 1-4 Alkyl) and -S(O)2NR x R y , R x and R y are each independently selected from hydrogen and C 1-4 Alkyl; the heterocycloalkyl group is optionally selected from one or more independently selected from -NR x R y Substituents substituted, R x and R y are each independently selected from hydrogen and C 1-4 alkyl; R 2A Selected from hydrogen and -O(C 1-4 alkyl); R 3 Selected from hydrogen, halogen and -C 1-4 alkyl; More preferably, in the compound of formula (IV), R 1 is selected from hydrogen, methyl, trifluoromethyl, cyclopropyl, Methoxy, R 2 is selected from hydrogen, halogen, methyl, isopropyl, trifluoromethyl, -SO2CH3, -SO2N(CH3)2, -CH2OCH3, R 2A is selected from hydrogen and methoxy; R 3 is selected from hydrogen, chlorine and methyl.

15. A compound or a pharmaceutically acceptable form thereof, wherein the compound is selected from: The pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable form thereof, or a mixture thereof, and one or more pharmaceutically acceptable carriers, and one or more pharmaceutically acceptable carriers.

17. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable form thereof, or a pharmaceutical composition according to claim 16, in the preparation of a medicament for preventing or treating a disease or condition associated with PKMYT1 activity; Preferably, the disease or condition associated with PKMYT1 activity is a tumor or cancer; Preferably, the tumor or cancer is a tumor or cancer with high CCNE1 gene expression / CCNE1 gene expansion or with FBXW7 gene inactivation mutation; Preferably, the cancer with high CCNE1 gene expression / CCNE1 gene expansion is uterine cancer, ovarian cancer, breast cancer, gastric cancer, esophageal cancer, lung cancer, liver cancer or endometrial cancer.

18. A method for preparing a compound according to any one of claims 1 to 15, comprising a fifth step, optionally a fourth step, optionally a third step, optionally a second step, optionally a first step, wherein the first to fifth steps are as follows: Step 1: Compound S-1 undergoes a coupling reaction with compound S-1-1 to generate compound S-2; Step 2: Compound S-2 removes the leaving group to generate compound S-3; Step 3: Compound S-3 undergoes coupling reaction with compound S-3-1 to generate compound S-4; Step 4: Compound S-4 reacts with compound S-4-1 to generate compound S-5; Step 5: Compound S-5 undergoes deprotection and hydrolysis to generate a compound of formula I; in Y 1 CR 4 ; X 1 is halogen (such as iodine, bromine or chlorine) or C optionally substituted by halogen 1-6 Alkyl sulfonate (such as triflate), preferably halogen; PG 1 is a protecting group for hydrogen or amino (such as methyl, tert-butyloxycarbonyl, trityl, tetrahydro-2H-pyran-2-yl, tert-butyldimethylsilyl, triisopropylsilyl, benzyl and methoxymethyl, etc.), preferably tetrahydro-2H-pyran-2-yl; LG 1 A leaving group that is hydrogen or amino (such as benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, etc.); is the leaving group of the amino group, where LG 2 is phenyl, 4-methoxyphenyl, etc., preferably phenyl; X, Z, R 1 , R 2 , R 3 , R 4 and R 5 The group is as defined in any one of claims 1 to 15; Preferably, the method for preparing the compound comprises the first to fifth steps mentioned above.

19. A method for preparing a compound according to any one of claims 1 to 15, which is selected from the following methods: Method 2, which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), wherein steps (1) to (5) are as shown in route A: Route A in: Step (1) reacting compound IA-1 with compound IA-2 to generate compound IA-3; Step (2) subjecting compound IA-3 to a ring-closing reaction to generate compound IA-4; Step (3) protecting compound IA-4 with Boc to generate compound IA-5; Step (4) coupling reaction of compound IA-5 and compound IA-6 to generate compound IA-7; Step (5) hydrolyzing and deprotecting compound IA-7 to generate compound IA-8; in: m and n are each independently 0, 1 or 2; represents a 4-8 membered saturated or partially saturated heterocyclic ring containing N; R 7 are independently selected from deuterium, halogen, -CN, oxo, hydroxyl, -C 1-6 Alkyl, -C 1-6 Haloalkyl, -C 1-6 Alkyl-OH, -O(C 1-6 Alkyl), -OC 1-6 Alkyl-OH, -NR x R y , -C 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl; Method 3, which comprises step (2), and optionally further comprises step (1), wherein steps (1) to (2) are as shown in route B1: Route B1 in Step (1) subjecting compound IB-0 to a coupling reaction to generate compound I-B1-1; Step (2) hydrolyzing and deprotecting compound I-B1-1 to generate compound I-B1-2; Method 4, which comprises step (6), optionally further comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), wherein steps (1) to (6) are as shown in route B2: Route B2 in: Step (1) hydrolyzing compound IB-0 to generate compound I-B2-1; Step (2) Boc protection is performed on compound I-B2-1 to generate compound I-B2-2; Step (3) deprotecting compound I-B2-2 to generate compound I-B2-3; Step (4) reacting compound I-B2-3 with I-B2-4 to generate compound I-B2-5; Step (5) hydrolyzing compound I-B2-5 to generate compound I-B2-6; Step (6) subjecting compound I-B2-6 to a deprotection reaction to generate compound I-B2-7; Wherein, X is halogen, preferably bromine; Method 5, which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), and optionally further comprises step (1), wherein steps (1) to (5) are as shown in route C1: Route C1 in: Step (1) allowing compound IB-0 to undergo a suzuki reaction with I-C1-1 to generate compound I-C1-2; Step (2) subjecting compound I-C1-2 to a Boc reaction to generate compound I-C1-3; Step (3) subjecting compound I-C1-3 to an oxidation bond breaking and then reduction reaction to generate compound I-C1-4; Step (4) hydrolyzing compound I-C1-4 to generate compound I-C1-5; Step (5) subjecting compound I-C1-5 to a deprotection reaction to generate compound I-C1-6; Wherein, n=0 or 1; Method 6, which comprises step (3), optionally further comprises step (2), optionally further comprises step (1), wherein steps (1) to (3) are as shown in route C2: Route C2 in: Step (1) subjecting compound I-C1-4 to a substitution reaction to generate compound I-C2-1; Step (2) hydrolyzing compound I-C2-1 to generate compound I-C2-2; Step (3) subjecting compound I-C2-2 to a deprotection reaction to generate compound I-C2-3; Wherein, n=0 or 1; Method 7, which comprises step (5), optionally further comprises step (4), optionally further comprises step (3), optionally further comprises step (2), optionally further comprises step (1), wherein steps (1) to (5) are as shown in route C3: Route C3 in: Step (1) subjecting compound I-C3-1 to a halogenation reaction to generate compound I-C3-2; Step (2) allowing compound I-C3-2 to undergo a substitution reaction with I-C3-3 to generate compound I-C3-4; Step (3) subjecting compound I-C3-4 to a Boc reaction to generate compound I-C3-5; Step (4) hydrolyzing compound I-C3-5 to generate compound I-C3-6; Step (5) deprotecting compound I-C3-6 to generate compound I-C3-7; in X is halogen such as bromine, iodine, chlorine, preferably bromine; In methods 2 to 7, PG 1 is a protecting group for hydrogen or amino (such as methyl, tert-butyloxycarbonyl, trityl, tetrahydro-2H-pyran-2-yl, tert-butyldimethylsilyl, triisopropylsilyl, benzyl and methoxymethyl, etc.), preferably tetrahydro-2H-pyran-2-yl; R 1 As defined in any one of claims 1 to 15.